[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2044
1. Mortazavi H, Abedini R, Sadri F, Soori T, Vasheghani-Farahani A: Crusted scabies in a patient with brain astrocytoma: report of a case. Int J Infect Dis; 2010 Jun;14(6):e526-7
MedlinePlus Health Information. consumer health - Scabies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crusted scabies in a patient with brain astrocytoma: report of a case.
  • He suffered from a brain tumor (astrocytoma) and was immunosuppressed because he was receiving systemic steroids and chemo-radiation therapy.
  • He also had psychomotor retardation and behavior changes due to the pressure effect of his brain tumor.
  • The diagnosis of crusted scabies was established based on direct positive skin smears from the lesions.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Sarcoptes scabiei. Scabies / diagnosis
  • [MeSH-minor] Adult. Animals. Diagnosis, Differential. Fatal Outcome. Humans. Immunocompromised Host. Male. Pruritus / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19700360.001).
  • [ISSN] 1878-3511
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


2. Martínez C, Molina JA, Alonso-Navarro H, Jiménez-Jiménez FJ, Agúndez JA, García-Martín E: Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol; 2010;10:71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma.
  • Aiming to identify genetic variations related to the risk of developing brain tumors, we investigated the putative association between common nonsynonymous PON1 polymorphisms and the risk of developing astrocytoma and meningioma.
  • METHODS: Seventy one consecutive patients with brain tumors (43 with astrocytoma grade II/III and 28 with meningioma) with ages ranging 21 to 76 years, and 220 healthy controls subjects were analyzed for the frequency of the nonsynonymous PON1 genotypes L55M rs854560 and Q192R rs662.
  • RESULTS: The frequencies of the PON1 genotypes and allelic variants of the polymorphisms PON1 L55M and PON1 Q192R did not differ significantly between patients with astrocytoma and meningioma and controls.
  • The minor allele frequencies were as follows: PON1 55L, 0.398, 0.328 and 0.286 for patients with astrocytoma, meningioma and control individuals, respectively; PON1 192R, 0.341, 0.362 and 0.302 for patients with astrocytoma, meningioma and control individuals, respectively.
  • Haplotype association analyses did not identify any significant association with the risk of developing astrocytoma or meningioma.
  • CONCLUSIONS: Common nonsynonymous PON1 polymorphisms are not related with the risk of developing astrocytoma and meningioma.
  • [MeSH-major] Aryldialkylphosphatase / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 1998 Sep;34(3):252-60 [9698994.001]
  • [Cites] Atherosclerosis. 1998 Aug;139(2):341-9 [9712341.001]
  • [Cites] Biochem Pharmacol. 1998 Sep 1;56(5):547-51 [9783722.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):116-25 [15386358.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Environ Health Perspect. 2005 May;113(5):546-51 [15866761.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):909-13 [16002382.001]
  • [Cites] Liver Int. 2005 Oct;25(5):935-9 [16162149.001]
  • [Cites] Toxicology. 2005 Nov 15;215(3):182-90 [16102884.001]
  • [Cites] Occup Environ Med. 2005 Nov;62(11):786-92 [16234405.001]
  • [Cites] World J Gastroenterol. 2006 Jan 28;12(4):615-20 [16489678.001]
  • [Cites] Acta Neurol Scand. 2006 May;113(5):322-6 [16629768.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1513-6 [16685388.001]
  • [Cites] Pharmacogenomics. 2006 Jul;7(5):711-8 [16886896.001]
  • [Cites] Cell Biochem Funct. 2006 Sep-Oct;24(5):455-60 [16142697.001]
  • [Cites] J Agric Saf Health. 2006 Nov;12(4):255-74 [17131948.001]
  • [Cites] Drug Metab Dispos. 2007 Feb;35(2):315-20 [17132760.001]
  • [Cites] Occup Environ Med. 2007 Aug;64(8):509-14 [17537748.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):559-75 [17701901.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2007 Jan-Mar;10(1-2):81-99 [18074305.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jan;18(1):37-43 [18216720.001]
  • [Cites] Am J Epidemiol. 2008 Apr 15;167(8):976-85 [18299277.001]
  • [Cites] Clin Chem. 2008 Aug;54(8):1390-4 [18664443.001]
  • [Cites] Curr Drug Metab. 2008 Jul;9(6):520-31 [18680472.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):709-15 [18682580.001]
  • [Cites] Psychiatr Genet. 2008 Dec;18(6):289-94 [19018234.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Apr 15;236(2):142-53 [19371602.001]
  • [Cites] Cell Biochem Funct. 2009 Dec;27(8):558-67 [19902425.001]
  • [Cites] Environ Health Perspect. 2010 Jan;118(1):144-9 [20056567.001]
  • [Cites] Adv Exp Med Biol. 2010;660:47-60 [20221870.001]
  • [Cites] Eur J Neurol. 2010 Jun 1;17(6):879-81 [20050883.001]
  • [Cites] Chem Biol Interact. 2010 Sep 6;187(1-3):355-61 [20338154.001]
  • [Cites] Neuromolecular Med. 2010 Sep;12(3):217-23 [19826962.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Feb;45(1):15-23 [10099836.001]
  • [Cites] Pharmacogenetics. 2000 Dec;10(9):767-79 [11191881.001]
  • [Cites] J Lipid Res. 2001 Apr;42(4):528-35 [11290824.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 15;173(1):1-6 [11350209.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1323-6 [11470765.001]
  • [Cites] Environ Health Perspect. 2001 Sep;109(9):909-13 [11673119.001]
  • [Cites] Ann Diagn Pathol. 2002 Feb;6(1):44-8 [11842378.001]
  • [Cites] Curr Opin Lipidol. 2002 Aug;13(4):357-62 [12151850.001]
  • [Cites] Am J Ind Med. 2002 Sep;42(3):214-27 [12210690.001]
  • [Cites] Cancer Causes Control. 2003 Mar;14(2):139-50 [12749719.001]
  • [Cites] Br J Neurosurg. 2003 Apr;17(2):182-4 [12820764.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1162-9 [14574645.001]
  • [Cites] J Mol Med (Berl). 2003 Dec;81(12):766-79 [14551701.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Am J Ind Med. 2004 May;45(5):395-407 [15095422.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Arch Pathol Lab Med. 1979 Dec;103(13):676-9 [583126.001]
  • [Cites] J Neurol. 1982;227(3):165-9 [6181224.001]
  • [Cites] Indian J Cancer. 1983 Mar;20(1A):86-8 [6873998.001]
  • [Cites] Am J Epidemiol. 1988 Oct;128(4):778-85 [3421243.001]
  • [Cites] Neurologia. 1988 Mar-Apr;3(2):68-70 [2856211.001]
  • [Cites] J Neurosci Nurs. 1992 Oct;24(5):260-4 [1328422.001]
  • [Cites] Am J Hum Genet. 1993 Mar;52(3):598-608 [7916578.001]
  • [Cites] Nat Genet. 1993 Jan;3(1):73-6 [8098250.001]
  • [Cites] Neurosurgery. 1995 Mar;36(3):599-604; discussion 604-5 [7753363.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4237-9 [7671227.001]
  • [Cites] J Neurosurg Sci. 1995 Mar;39(1):27-35 [8568553.001]
  • [Cites] Epidemiol Rev. 1995;17(2):382-414 [8654518.001]
  • [Cites] Curr Opin Lipidol. 1996 Apr;7(2):69-76 [8743898.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):334-6 [8896566.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Nature. 1998 Jul 16;394(6690):284-7 [9685159.001]
  • (PMID = 20723250.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.8.1 / Aryldialkylphosphatase; EC 3.1.8.1 / PON1 protein, human
  • [Other-IDs] NLM/ PMC2936881
  •  go-up   go-down


3. Azad S, Kudesia S, Chawla N, Azad R, Singhal M, Rai SM, Arora P: Pilomyxoid astrocytoma. Indian J Pathol Microbiol; 2010 Apr-Jun;53(2):294-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid astrocytoma.
  • Pilomyxoid astrocytoma (PMA) is a recently described brain tumor.
  • PMA shares similar features with pilocytic astrocytoma (PA), the most common central nervous system (CNS) tumor in the pediatric population, yet displays subtle histologic differences.
  • The histological findings revealed a tumor composed of a monotonous population of loosely arranged cells with delicate piloid like processes, within a prominent myxoid background.
  • The tumor lacked biphasic appearance, Rosenthal fibers, eosinophilic granular bodies and calcification that are commonly observed in classical PA.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / pathology. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology
  • [MeSH-minor] Brain / radiography. Child. Developmental Disabilities / etiology. Histocytochemistry. Humans. Male. Microscopy. Sella Turcica / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551536.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. Rashid MH, Ahmad SU, Rahman MH, Raihan MZ, Sayed MA: Surgical outcome of low grade astrocytoma of brain. Mymensingh Med J; 2010 Apr;19(2):185-90
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome of low grade astrocytoma of brain.
  • This study was carried out in the department of Neurosurgery, Dhaka Medical College Hospital, Dhaka, Bangladesh, during the period of January 2003 to December 2006 to elucidate the effectiveness of surgical treatment in the management of low grade astrocytoma of brain.
  • For this purpose, a total number of 50 cases admitted during the study period with low grade astrocytoma of brain supported by clinical features and radiological investigations (CT and MRI scan) were included in this study.
  • Out of 50 patients 60.0% had gross total removal of tumor and 40.0% sub total tumor resection.
  • Histopathological study was done in all cases after tumor resection.
  • Among the gross total tumor removal cases highest percentage had good recovery (93.4%) in the immediate post operative period.
  • Another 2(4.0%), those underwent subtotal tumor resection died during subsequent follow up period at 8th and 14th postoperative day.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395910.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


5. Kostic A, Mihailovic D, Veselinovic S, Tasic D, Stefanovic I, Novak V, Stojanovic N, Veselinovic D, Pavlovic S: Tumor size and karyometric variables in brain astrocytoma. J BUON; 2009 Jul-Sep;14(3):473-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor size and karyometric variables in brain astrocytoma.
  • PURPOSE: To show any possible correlation of some karyometric variables with tumor size in patients with brain astrocytoma, in order to confirm karyometry as an objective histological method.
  • PATIENTS AND METHODS: The study included 63 patients of different ages and both genders with brain astrocytoma histologically confirmed on the surgically removed material.
  • In all patients maximal tumor excision was done, and all were postoperatively treated according to different therapeutic protocols.
  • Tumor size (preoperative CT scan) was correlated with the duration of survival and the values of some karyometric tumor variables: area, density, maximal axis, mean axis, minimal axis, circumference, roundness, integrated optical density (IOD) and number of nuclei.
  • RESULTS: Patients were separated into 3 groups according to the average tumor diameter.
  • Seven out of 9 examined karyometric variables were significantly related (p<0.05) to the tumor size: area, maximal axis, mean axis, minimal axis, circumference, roundness and IOD.
  • The results of our morphometric analysis of the tumor cell nuclei, after correlation with CT findings, revealed that nuclear pleomorphism and larger nuclear size are associated with larger brain astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Nucleus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810141.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


6. Tchaicha JH, Mobley AK, Hossain MG, Aldape KD, McCarty JH: A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis. Oncogene; 2010 Aug 5;29(31):4460-72
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis.
  • Furthermore, little is known about how cancer cells selectively circumvent the actions of these inhibitors to promote pathological angiogenesis, a requisite event for tumor progression.
  • Using mosaic mouse models of the malignant brain cancer, astrocytoma, we report that tumor cells induce pathological angiogenesis by suppressing expression of the ECM protein receptor alphavbeta8 integrin.
  • Diminished integrin expression in astrocytoma cells leads to reduced activation of latent TGFbetas, resulting in impaired TGFbeta receptor signaling in tumor-associated endothelial cells.
  • These data reveal that astrocytoma cells manipulate their angiogenic balance by selectively suppressing alphavbeta8 integrin expression and function.
  • Finally, these results show that an adhesion and signaling axis normally involved in developmental brain angiogenesis is pathologically exploited in adult brain tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Methods Enzymol. 2006;419:3-23 [17141049.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] J Cell Sci. 2007 May 15;120(Pt 10):1810-7 [17502485.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78 [17522591.001]
  • [Cites] Glia. 2007 Aug 1;55(10):1023-33 [17549683.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] Mech Dev. 2008 May-Jun;125(5-6):508-16 [18343643.001]
  • [Cites] Am J Pathol. 2008 Jun;172(6):1740-7 [18467691.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1129-33 [18948956.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3308-16 [19351861.001]
  • [Cites] Curr Opin Hematol. 2009 May;16(3):209-14 [19318941.001]
  • [Cites] J Cell Sci. 2009 Jun 1;122(Pt 11):1842-51 [19461074.001]
  • [Cites] Cell Adh Migr. 2009 Apr-Jun;3(2):199-204 [19363295.001]
  • [Cites] Cell Adh Migr. 2009 Apr-Jun;3(2):211-5 [19372738.001]
  • [Cites] Nat Rev Cancer. 2010 Jan;10(1):9-22 [20029421.001]
  • [Cites] Oncogene. 2010 Mar 4;29(9):1351-61 [20010874.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 [11121071.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):4956-60 [11431323.001]
  • [Cites] Mol Cell Neurosci. 2001 Jul;18(1):108-18 [11461157.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6674-8 [11559533.001]
  • [Cites] Development. 2002 Jun;129(12):2891-903 [12050137.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5551-8 [12359767.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(21):7667-77 [12370313.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1962-8 [12702589.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2751-8 [15087390.001]
  • [Cites] Anal Biochem. 1994 Feb 1;216(2):276-84 [8179182.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2746-51 [7796398.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8502-7 [8710899.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8761-6 [9238051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12081-7 [9342366.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Development. 2005 Jan;132(1):165-76 [15576410.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):229-43 [15674480.001]
  • [Cites] Am J Pathol. 2005 Jun;166(6):1883-94 [15920172.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13479-83 [16157875.001]
  • [Cites] Curr Top Dev Biol. 2005;69:67-99 [16243597.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1379-87 [16251422.001]
  • [Cites] J Neurosci. 2005 Oct 26;25(43):9940-8 [16251442.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • (PMID = 20531304.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NINDS NIH HHS / NS / R01 NS059876-03; United States / NINDS NIH HHS / NS / R01NS059876; United States / NCI NIH HHS / CA / P50CA127001; United States / NINDS NIH HHS / NS / R01 NS059876-02S2; United States / NINDS NIH HHS / NS / R01 NS059876; United States / NCI NIH HHS / CA / P50 CA127001; United States / NINDS NIH HHS / NS / NS059876-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Integrins; 0 / integrin alphavbeta8
  • [Other-IDs] NLM/ NIHMS198457; NLM/ PMC3037767
  •  go-up   go-down


7. Allerstorfer S, Sonvilla G, Fischer H, Spiegl-Kreinecker S, Gauglhofer C, Setinek U, Czech T, Marosi C, Buchroithner J, Pichler J, Silye R, Mohr T, Holzmann K, Grasl-Kraupp B, Marian B, Grusch M, Fischer J, Micksche M, Berger W: FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. Oncogene; 2008 Jul 10;27(30):4180-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report simultaneous overexpression of FGF5 and its predominant high-affinity receptor (FGFR1 IIIc) in astrocytic brain tumour specimens (N=49) and cell cultures (N=49).
  • Moreover, tumour cell migration was distinctly stimulated by rFGF5 but attenuated by FGF5 siRNA.
  • In summary, we demonstrate for the first time that FGF5 contributes to the malignant progression of human astrocytic brain tumours by both autocrine and paracrine effects.
  • [MeSH-major] Autocrine Communication / physiology. Brain Neoplasms / genetics. Fibroblast Growth Factor 5 / physiology. Glioblastoma / genetics. Oncogenes. Paracrine Communication / physiology
  • [MeSH-minor] Cell Death / drug effects. Cell Movement / drug effects. Cell Proliferation / drug effects. Culture Media, Conditioned / pharmacology. Disease Progression. Genes, Dominant / physiology. Humans. Mutant Proteins / genetics. Mutant Proteins / physiology. Neovascularization, Pathologic / chemically induced. Neovascularization, Pathologic / genetics. Recombinant Proteins / pharmacology. Transfection. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res Mol Brain Res. 1996 May;38(1):161-5 [8737680.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15292-7 [8663044.001]
  • [Cites] Vet Pathol. 1997 May;34(3):171-9 [9163872.001]
  • [Cites] Oncogene. 1997 Sep 18;15(12):1417-24 [9333017.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1998;59:135-76 [9427842.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):352-61 [9443417.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):189-95; discussion 196 [9457270.001]
  • [Cites] Biochem Cell Biol. 1997;75(6):669-85 [9599656.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Jul;286(1):569-77 [9655904.001]
  • [Cites] Neurosurgery. 1998 Aug;43(2):337-46 [9696088.001]
  • [Cites] J Biol Chem. 1998 Oct 30;273(44):29262-71 [9786939.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5285-90 [9850049.001]
  • [Cites] J Invest Dermatol. 1998 Dec;111(6):963-72 [9856803.001]
  • [Cites] Int J Cancer. 1999 Oct 29;83(3):415-23 [10495436.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jun;131(6):355-63 [15856298.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):139-49 [15863030.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86 [15863033.001]
  • [Cites] Growth Factors. 2005 Jun;23(2):87-95 [16019430.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6 [16046538.001]
  • [Cites] Biochem Pharmacol. 2006 Feb 14;71(4):426-40 [16343446.001]
  • [Cites] J Cell Sci. 2006 Feb 1;119(Pt 3):459-69 [16418217.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3584-92 [16585183.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):281-93 [16554966.001]
  • [Cites] Mol Cancer Res. 2006 Dec;4(12):927-34 [17189383.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):960-9 [17342095.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4055-63 [17720881.001]
  • [Cites] J Neurosci. 2003 Jul 23;23(16):6404-12 [12878680.001]
  • [Cites] Cell Tissue Res. 2003 Aug;313(2):139-57 [12845521.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3487-95 [3211147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(20):8022-6 [1700424.001]
  • [Cites] Mol Cell Biol. 1991 Apr;11(4):1840-5 [2005884.001]
  • [Cites] Development. 1991 Jun;112(2):397-406 [1794310.001]
  • [Cites] J Invest Dermatol. 2000 Mar;114(3):456-63 [10692103.001]
  • [Cites] Glia. 2000 May;30(3):231-41 [10756073.001]
  • [Cites] Nat Cell Biol. 2001 Jul;3(7):650-7 [11433297.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5511-6 [11454700.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):329-39 [11839785.001]
  • [Cites] Int J Pancreatol. 2001;29(2):85-92 [11876253.001]
  • [Cites] Neurol Res. 2002 Apr;24(3):244-8 [11958417.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):773-80 [12574212.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):209-14 [8381111.001]
  • [Cites] Neuron. 1993 Mar;10(3):369-77 [8461132.001]
  • [Cites] Brain Res. 1993 Mar 19;606(1):79-86 [8462006.001]
  • [Cites] Eur J Neurosci. 1994 Feb 1;6(2):244-52 [8167846.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2794-9 [8168112.001]
  • [Cites] Cell. 1994 Sep 23;78(6):1017-25 [7923352.001]
  • [Cites] J Neurooncol. 1994;18(3):207-16 [7964981.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):171-83 [9010219.001]
  • (PMID = 18362893.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / FWF/ P 19920
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / FGF5 protein, human; 0 / Mutant Proteins; 0 / Recombinant Proteins; 129653-64-1 / Fibroblast Growth Factor 5
  • [Other-IDs] NLM/ PMC2879862; NLM/ UKMS30927
  •  go-up   go-down


8. Santhosh K, Kesavadas C, Radhakrishnan VV, Abraham M, Gupta AK: Multifocal desmoplastic noninfantile astrocytoma. J Neuroradiol; 2008 Dec;35(5):286-91
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal desmoplastic noninfantile astrocytoma.
  • This is a report of a case of multifocal desmoplastic astrocytoma in an 11-year-old child in which we describe the MRI findings and discuss the possible mechanism of its development.
  • The MRI appearances in our case support the view that the tumor is primarily of leptomeningeal or superficial cortical origin, with cystic formation secondary to entrapment of cerebrospinal fluid.
  • Desmoplastic astrocytoma at a noninfantile age is extremely rare: only four cases have been reported in the literature so far.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Child. Contrast Media. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538396.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


9. Li M, Jia ZZ, Gu HM, Zhou XJ, Tang LM: [Application of apparent diffusion coefficient and fractional anisotropy in identification of tumor component and grading of brain astrocytoma]. Zhonghua Yi Xue Za Zhi; 2008 Dec 23;88(47):3352-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of apparent diffusion coefficient and fractional anisotropy in identification of tumor component and grading of brain astrocytoma].
  • OBJECTIVE: To evaluate the value of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) in identification of tumor element and grading of brain astrocytoma.
  • METHODS: Thirty-three patients with histologically confirmed astrocytoma underwent diffusion weighted imaging (DWI), diffusion tensor imaging (DTI), and conventional MRI before operation.
  • The values of ADC and FA of different regions in the same tumor and of astrocytoma of different grades were measured and compared.
  • RESULTS: The ADC values of the tumor parenchyma, necrotic region, peritumoral edema region were (1.28 +/- 0.44), (1.97 +/- 0.53), and (1.74 +/- 0.47) respectively, all significantly higher than that of the corresponding normal brain tissues [(0.80 +/- 0.18), P = 0.009, P = 0.000, P = 0.000] with significantly differences between the tumor parenchyma and necrotic region and peritumoral edema region (both P < 0.05), however, there was not significant difference between the necrotic region and peritumoral edema region.
  • The FA values of the tumor parenchyma, necrotic region, and peritumoral edema region were (0.18 +/- 0.07), (0.14 +/- 0.05), and (0.16 +/- 0.05) respectively, all significantly higher than that of the corresponding normal brain tissues [(0.58 +/- 0.10), all P = 0.000], without significant differences among the former 3 groups.
  • There were no significant differences in the ADC and FA values among the tumors at different grades, however, there was a tendency of ADC to decrease and of FA to increase along the increase of grade of tumor, although not significantly.
  • CONCLUSION: ADC value plays an important part in distinguishing tumor components and determining tumor boundary, and plays a certain role in judging the grade of astrocytomas.
  • FA value is vital to determine the tumor boundary, and has certain value in differentiating high-grade from low-grade astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Anisotropy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19257968.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


10. Lu ZQ, Wang YM, Cao YY, Zhang QJ, Zhang XH, Li YH, Wang HS, Xie HL, Jiao BH, Zhang JH: [Correlations of polymorphisms in matrix metalloproteinase-3 and -7 promoters to susceptibility to brain astrocytoma]. Ai Zheng; 2007 May;26(5):463-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of polymorphisms in matrix metalloproteinase-3 and -7 promoters to susceptibility to brain astrocytoma].
  • BACKGROUND & OBJECTIVE: Matrix metalloproteinases (MMPs) are key enzymes involved in tumor development, invasion and metastasis.
  • The single nucleotide polymorphisms (SNPs) in the promoter regions of MMP genes may influence tumor development and progression via modulating mRNA transcription and protein expression.
  • This study was to explore the correlations of the promoter SNPs in MMP-3 and MMP-7 genes to susceptibility to brain astrocytoma.
  • METHODS: The genotype of MMP-3 -1171 5A/6A and MMP-7 -181A/G polymorphisms in 236 patients with brain astrocytoma and 366 healthy controls was detected by polymerase chain reaction-restrictive fragment length polymorphism (PCR-RFLP).
  • RESULTS: The allelotype and overall genotype distribution of MMP-3 SNP among the astrocytoma patients and healthy controls were similar (P>0.05).
  • Stratified by sex, age, and histological grade, the susceptibility to brain astrocytoma among the subjects with 5A/5A and 5A/6A genotypes and the subjects with 6A/6A genotype were similar(P>0.05).
  • The overall genotype distribution of MMP-7 SNP among the astrocytoma patients and healthy controls were significantly different (P = 0.001).
  • Compared with the A/A genotype, both the G/G and the A/G genotypes significantly increased the susceptibility to astrocytoma [sex-and age-adjusted odds ratio (OR) = 2.77 and 1.69, 95% confidence interval (CI)=1.27-6.02 and 1.01-2.84, respectively].
  • Stratification analysis showed that the G/G genotype significantly increased the susceptibility to astrocytoma in men (adjusted OR = 3.24, 95% CI = 1.12-9.41) and in the individuals younger than 45 years (adjusted OR = 3.16, 95% CI = 1.09-9.16).
  • When stratified by histological grade, the A/G genotype increased the susceptibility to grade II astrocytoma by about 2 folds (adjusted OR = 2.06, 95% CI = 1.05 - 4.05), while the G/G genotype increased the susceptibility to grade II-IV astrocytoma by about 3 folds.
  • CONCLUSION: MMP-7 -181A/G polymorphism may influence the susceptibility to astrocytoma, while MMP-3-1171 5A/6A polymorphism has no correlation to the susceptibility.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genetic Predisposition to Disease. Matrix Metalloproteinase 3 / genetics. Matrix Metalloproteinase 7 / genetics. Polymorphism, Single Nucleotide

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672933.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.4.24.17 / MMP3 protein, human; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


11. Kostic A, Mihailovic D, Veselinovic S, Tasic G, Radulovic D, Stefanovic I: Peritumoral edema and karyometric variables in astrocytoma of the brain. J BUON; 2007 Apr-Jun;12(2):239-43
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral edema and karyometric variables in astrocytoma of the brain.
  • PURPOSE: The aim of this study was to evaluate karyometry as a quantitative and objective histological method by showing correlation of some karyometric variables with the severity of peritumoral edema in patients with brain astrocytoma.
  • The patients were diagnosed with astrocytoma of the brain, histologically confirmed on the surgically removed material.
  • Maximal tumor excision was performed in all patients, who were postoperatively treated according to current oncologic therapeutic protocols.
  • The intensity of perifocal edema (preoperative CT scan) was correlated to the duration of survival and the values of 9 karyometric tumor variables: area, density, maximal axis, mean axis, circumference, roundness, integrated optical density and number of nuclei.
  • Correlation of karyometric variables with CT findings revealed that higher degrees of tumor cellularity and nuclear wrinkling with increased integrated optical density is associated with larger peritumoral edema.
  • [MeSH-major] Astrocytoma / pathology. Brain Edema / pathology. Brain Neoplasms / pathology

  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600879.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Olivera M, Martínez C, Molina JA, Alonso-Navarro H, Jiménez-Jiménez FJ, García-Martín E, Benítez J, Agúndez JA: Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma. Acta Neurol Scand; 2006 May;113(5):322-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased frequency of rapid acetylator genotypes in patients with brain astrocytoma and meningioma.
  • We investigated the association between the genetic NAT2 polymorphism and brain tumors by analysis of genomic DNA from 71 brain tumor patients and 258 healthy controls.
  • A higher number of individuals carrying functional NAT2 genes, and therefore with a rapid acetylation phenotype, was found in brain tumor patients vs healthy volunteers (OR 1.79, 95% CI 1.05-3.05; P < 0.05).
  • This is observed either for patients suffering from meningioma or astrocytoma, and this is due to an increase of the wild-type NAT2*4 allelic variant frequency (OR 1.48, 95% CI 0.99-2.19), and a reduction of the commonest defective allelic variant NAT2*5B in the brain tumor patients, compared with healthy subjects (OR 0.54, 95% CI 0.37-0.80).
  • CONCLUSIONS: This observation indicates that NAT2 could be considered as a low-penetrance gene for brain tumors, and that individuals carrying rapid acetylation alleles are at increased risk of developing brain tumors.
  • [MeSH-major] Arylamine N-Acetyltransferase / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Polymorphism, Single Nucleotide / genetics

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629768.001).
  • [ISSN] 0001-6314
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


13. Banerjee HN, Zhang L: Deciphering the finger prints of brain cancer astrocytoma in comparison to astrocytes by using near infrared Raman spectroscopy. Mol Cell Biochem; 2007 Jan;295(1-2):237-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deciphering the finger prints of brain cancer astrocytoma in comparison to astrocytes by using near infrared Raman spectroscopy.
  • To explore the biochemical differences between brain cancer cells Astrocytoma and normal cells Astrocyte, we investigated the Raman spectra of single cell from these two cell types and analyzed the difference in spectra and intensity.
  • The Raman spectra of brain cancer cells was similar to those of normal cells, but the Raman intensity of cancer cells was much higher than that of normal cells.
  • The Raman spectra of brain cancer Astrocytoma shows that the structural changes of cancer cells happen so that many biological functions of these cells are lost.
  • The results indicate that Raman spectra can offer the experimental basis for the cancer diagnosis and treatment.
  • [MeSH-major] Astrocytes / chemistry. Astrocytoma / chemistry. Brain Neoplasms / chemistry. Spectroscopy, Near-Infrared. Spectrum Analysis, Raman

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924417.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / G11HD 34280-05
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Lee WH, Jin JS, Tsai WC, Chen YT, Chang WL, Yao CW, Sheu LF, Chen A: Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma. Pathobiology; 2006;73(3):141-8
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma.
  • In nude mice, the growth of the tumor was inhibited by 30% by AS-CH or AS-AC (20 mg/kg; p < 0.05) and by 60% by AS-CH or AS-AC (60 mg/kg; p < 0.05).
  • CONCLUSIONS: Danggui may inhibit tumor growth by reducing the level of VEGF and the proapoptotic protein, cathepsin B.
  • [MeSH-major] Angelica sinensis / chemistry. Antineoplastic Agents / pharmacology. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Drugs, Chinese Herbal / pharmacology. Phytotherapy
  • [MeSH-minor] Adult. Animals. Apoptosis / drug effects. Cathepsin B / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Formazans / metabolism. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Plant Extracts / pharmacology. Tetrazolium Salts / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085958.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 0 / Formazans; 0 / Plant Extracts; 0 / Tetrazolium Salts; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 23305-68-2 / MTT formazan; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


15. Liu RS, Chang CP, Chu LS, Chu YK, Hsieh HJ, Chang CW, Yang BH, Yen SH, Huang MC, Liao SQ, Yeh SH: PET imaging of brain astrocytoma with 1-11C-acetate. Eur J Nucl Med Mol Imaging; 2006 Apr;33(4):420-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET imaging of brain astrocytoma with 1-11C-acetate.
  • Images were analysed by visual interpretation and determination of the tumour to cortex ratio (T/C ratio) and standardised uptake value (SUV).
  • The tumour uptake was visually scored into three grades as compared with the contralateral cortex: clearly lower (-), almost equal (+) and clearly higher (++).
  • ACE is complementary to FDG for the diagnosis and characterisation of astrocytoma.
  • [MeSH-major] Acetates. Astrocytoma / radionuclide imaging. Brain Neoplasms / radionuclide imaging. Carbon. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CARBON .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404596.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acetates; 0 / Radiopharmaceuticals; 0 / carbon-11 acetate; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7440-44-0 / Carbon
  •  go-up   go-down


16. Witt H, Korshunov A, Remke M, Janzarik WG, Gnekow A, Scheurlen W, Kulozik AE, Lichter P, Pfister S: DNA methylation pattern of brain stem pilocytic astrocytomas in children. J Clin Oncol; 2009 May 20;27(15_suppl):10021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation pattern of brain stem pilocytic astrocytomas in children.
  • : 10021 Background: Pilocytic astrocytoma (WHO grade I) comprises the most frequent brain tumor in childhood.
  • Although histologically indistinguishable, tumors with brain stem location have a particularly poor prognosis.
  • METHODS: To identify novel genes involved in astrocytoma pathogenesis, we performed a genome-wide DNA methylation analysis of 78 pilocytic astrocytoma samples from different tumor locations (diencephalic, cerebral, cerebellar, brain stem).
  • RESULTS: In this genome-wide approach, we identified an 11-gene signature that was able to correctly separate all brain stem tumors (n = 8) from the majority of tumors from other locations (56/70).
  • Moreover, from 14 tumors clustering together with the brain stem tumors, 5 patients experienced disease recurrence (38%) as opposed to 20% in the remaining group.
  • Genes contained in the signature most interestingly included three homeobox family genes (HOXB1, HOXD3, and HOXD4), and NES, a tumor stem cell marker.
  • CONCLUSIONS: These data suggest that brain stem pilocytic astrocytomas display biologic features different from most tumors of other locations and share a methylation signature with tumors prone to disease recurrence from other locations.
  • We provide first evidence for a role of differentially methylated homeobox family genes in the pathogenesis of pilocytic astrocytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Gathinji M, McGirt MJ, Attenello FJ, Chaichana KL, Than K, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa A: Association of preoperative depression and survival after resection of malignant brain astrocytoma. Surg Neurol; 2009 Mar;71(3):299-303, discussion 303
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of preoperative depression and survival after resection of malignant brain astrocytoma.
  • It remains unclear if clinical depression affects survival after surgical management of malignant brain astrocytoma.
  • We set out to determine whether patients with a diagnosis of clinical depression before surgery experienced decreased survival independent of treatment modality or degree of disability.
  • METHODS: One thousand fifty-two patients undergoing surgical management for malignant brain astrocytoma (WHO grade 3 or 4) performed at a single institution from 1995 to 2006 were retrospectively reviewed.
  • Forty-nine patients (5%) carried the diagnosis of depression at the time of surgery.
  • CONCLUSION: In our experience, patients who are actively depressed at the time of surgery were associated with decreased survival after surgical management of malignant astrocytoma, independent of degree of disability, tumor grade, or subsequent treatment modalities.
  • [MeSH-major] Astrocytoma / mortality. Brain Neoplasms / mortality. Depression / mortality

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786716.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kumar AJ, Leeds NE, Kumar VA, Fuller GN, Lang FF, Milas Z, Weinberg JS, Ater JL, Sawaya R: Magnetic resonance imaging features of pilocytic astrocytoma of the brain mimicking high-grade gliomas. J Comput Assist Tomogr; 2010 Jul;34(4):601-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging features of pilocytic astrocytoma of the brain mimicking high-grade gliomas.
  • OBJECTIVE: The typical magnetic resonance/computed tomographic imaging appearance of pilocytic astrocytoma (PA) is that of a cyst with an intensely enhancing mural nodule.
  • METHODS: One hundred patients referred to the cancer center with brain tumors histologically proven to be PA were retrospectively reviewed (95 by magnetic resonance imaging and 5 by computed tomographic imaging) and analyzed.
  • Tumor locations consisted of the following: optic chiasm (22), lateral ventricle (3), thalamus (12), basal ganglia (1), cerebral hemisphere (10), corpus callosum (2), brain stem (26), fourth ventricle (1), and cerebellum (23).
  • CONCLUSIONS: It is important to recognize the aggressive imaging appearance of PA (grade 1 astrocytoma) because it can be mistaken for high-grade gliomas and may thus lead to inappropriate therapy.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Brain / pathology. Brain / radiography. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed / methods. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657231.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Lu Z, Cao Y, Wang Y, Zhang Q, Zhang X, Wang S, Li Y, Xie H, Jiao B, Zhang J: Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China. J Neurooncol; 2007 Oct;85(1):65-73
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in the matrix metalloproteinase-1, 3, and 9 promoters and susceptibility to adult astrocytoma in northern China.
  • The single nucleotide polymorphisms (SNPs) in the promoter region of matrix metalloproteinase (MMP) genes may influence tumor occurrence and progression via modifying mRNA transcription and protein expression.
  • The study aims to explore the association of the SNPs in MMP-1, 3 and MMP-9 promoters with susceptibility to adult brain astrocytoma in northern China.
  • Genotyping for the MMP-1 -1607 2G/1G, MMP-3 -1171 5A/6A, and MMP-9 -1562 C/T SNPs were performed by PCR-RFLP methods among 236 adult astrocytoma patients and 366 healthy controls.
  • The results showed that the overall distribution of the MMP-1 allelotype and genotype among astrocytoma patients and healthy controls was significantly different (P = 0.002 and P < 0.001, respectively).
  • Compared with the 2G/2G genotype, the 1G/1G genotype significantly decreased the risk of astrocytoma development (adjusted OR = 0.58, 95% CI = 0.42-0.79).
  • The similar results were obtained when stratified by gender and age at tumor diagnosis (< or =45 or >45 years).
  • The association between MMP-3 -1171 5A/6A or MMP-9 -1562 C/T SNPs and susceptibility to astrocytoma was not observed in this study.
  • However, MMP-1 1G-MMP-3 6A haplotype significantly reduced the risk of astrocytoma development when using MMP-1 2G-MMP-3 6A haplotype as a reference (OR = 0.45, 95% CI = 0.29-0.67).
  • The present study suggested that, the MMP-1 -1607 1G/1G genotype and MMP-1 1G-MMP-3 6A haplotype may play protective role in the development of adult astrocytoma in northern Chinese, whereas the MMP-3 -1171 5A/6A and MMP-9 -1562 C/T polymorphisms may not be independent factors to influence susceptibility to adult astrocytoma in this population.
  • [MeSH-major] Astrocytoma / epidemiology. Astrocytoma / genetics. Brain Neoplasms / epidemiology. Brain Neoplasms / genetics. Matrix Metalloproteinase 1 / genetics. Matrix Metalloproteinase 3 / genetics. Matrix Metalloproteinase 9 / genetics. Polymorphism, Genetic / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adult. Case-Control Studies. China / epidemiology. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Genetic Linkage / genetics. Genotype. Haplotypes. Humans. Polymorphism, Single Nucleotide. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17502998.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


20. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H, Quiñones-Hinojosa AR: Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg; 2009 Jan;110(1):156-62
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
  • OBJECT: With recent advances in the adjuvant treatment of malignant brain astrocytomas, it is increasingly debated whether extent of resection affects survival.
  • METHODS: The authors retrospectively reviewed the cases of 1215 patients who underwent surgery for malignant brain astrocytomas (World Health Organization [WHO] Grade III or IV) at a single institution from 1996 to 2006.
  • Surgery consisted of primary resection in 549 patients (58%) and revision resection for tumor recurrence in 400 patients (42%).
  • Adjusting for factors associated with survival for WHO Grade III astrocytoma (age, KPS score, and revision resection), GTR versus STR (p < 0.05) was associated with improved survival.
  • CONCLUSIONS: In the authors' experience with both primary and secondary resection of malignant brain astrocytomas, increasing extent of resection was associated with improved survival independent of age, degree of disability, WHO grade, or subsequent treatment modalities used.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18847342.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Decanoic Acids; 0 / Polyesters; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  •  go-up   go-down


21. Chu SH, Yuan XH, Jiang PC, Li ZQ, Zhang J, Wen ZH, Zhao SY, Chen XJ, Cao CJ: [The expression of hepatocyte growth factor and its receptor in brain astrocytomas]. Zhonghua Yi Xue Za Zhi; 2005 Mar 30;85(12):835-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of hepatocyte growth factor and its receptor in brain astrocytomas].
  • OBJECTIVE: To investigate the expression of hepatocyte growth factor (HGF) mRNA and its receptor (c-Met) mRNA in brain astrocytomas and their relationships with tumor proliferation, angiogenesis, clinical pathology and prognosis.
  • METHODS: The expression of HGF mRNA, c-Met mRNA in the resected tumor tissues of 76 patients with brain astrocytomas, 43 males and 33 females, aged 20 - 71, were detected by in situ hybridization.
  • RESULTS: The positive rates of expression of HGF, c-Met and PCNA in low pathologic grades of brain astrocytoma were 34.5%, 44.8% and 15% +/- 9% respectively, and in high pathologic grades of brain astrocytoma were 34.5%, 44.8% and 48% +/- 12% respectively (P < 0.05).
  • MVD in low and high pathologic grades of brain astrocytoma were 17 +/- 7 and 31 +/- 13 respectively (P < 0.05).
  • The expression of HGF, c-Met, PCNA and CD34 was not related to sex, age, position of tumor and diameter of tumor.
  • The expression of c-Met was related to the expression of HGF, PCNA and the MVD in the tumor tissues of these patients.
  • The pathological grade, position of tumor, HGF, c-Met, PCNA, MVD had a significant influence on the survival time.
  • CONCLUSION: HGF/c-Met plays an important role in the formation and progression of the brain astrocytoma and can promote tumor proliferation and intratumoral microvascular formation, and is closely related to the prognosis of the patients.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Hepatocyte Growth Factor / biosynthesis. Proto-Oncogene Proteins / biosynthesis. Receptors, Growth Factor / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic. Proto-Oncogene Proteins c-met. RNA, Messenger / biosynthesis. RNA, Messenger / genetics


22. Magalhaes A, Godfrey W, Shen Y, Hu J, Smith W: Proton magnetic resonance spectroscopy of brain tumors correlated with pathology. Acad Radiol; 2005 Jan;12(1):51-7
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopy of brain tumors correlated with pathology.
  • RATIONALE AND OBJECTIVES: Evaluate proton magnetic resonance spectroscopy ((1)H-MRS) for assessing and grading brain tumors.
  • In 16 patients with brain astrocytoma of various grades, the pathology grading was correlated with Cho/NAA and Cho/Cr.
  • These values were 6.53 and 3.35 for nine patients with Grade 4 astrocytoma; 1.85 and 1.62 for three patients with Grade 3 astrocytoma; 2.21 and 1.50 for three patients with Grade 2 astrocytoma; and 1.45 and 1.49 for one patient with Grade 1 astrocytoma.
  • CONCLUSION: MRS ratios can be used to differentiate malignant and nonmalignant lesions from normal brain tissue.
  • In general, high-grade astrocytoma have higher Cho/NAA and Cho/Cr ratios compared with low-grade astrocytoma.
  • [MeSH-major] Aspartic Acid / analogs & derivatives. Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / pathology. Brain / pathology. Choline / analysis. Creatine / analysis. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Glioma / diagnosis. Glioma / pathology. Gliosarcoma / diagnosis. Gliosarcoma / pathology. Humans. Hydrogen. Image Processing, Computer-Assisted / methods. Male. Middle Aged. Oligodendroglioma / diagnosis. Oligodendroglioma / pathology. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROGEN .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691725.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 30KYC7MIAI / Aspartic Acid; 7YNJ3PO35Z / Hydrogen; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


23. Eddaoudi A, Townsend-Nicholson A, Timms JF, Schorge S, Jayasinghe SN: Molecular characterisation of post-bio-electrosprayed human brain astrocytoma cells. Analyst; 2010 Oct;135(10):2600-12
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterisation of post-bio-electrosprayed human brain astrocytoma cells.
  • [MeSH-minor] Astrocytoma. Brain Neoplasms. Calcium / metabolism. Cell Survival. Electrophoresis, Gel, Two-Dimensional. Humans. Indoles / pharmacology. Maleimides / pharmacology. Potassium Channels / metabolism. Receptor, Muscarinic M3 / genetics. Receptor, Muscarinic M3 / metabolism. Transfection. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / pharmacology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694206.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G0601440; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Indoles; 0 / Maleimides; 0 / Potassium Channels; 0 / Receptor, Muscarinic M3; 0 / Tumor Necrosis Factor-alpha; 0 / bisindolylmaleimide VIII; SY7Q814VUP / Calcium
  •  go-up   go-down


24. Weber RG, Hoischen A, Ehrler M, Zipper P, Kaulich K, Blaschke B, Becker AJ, Weber-Mangal S, Jauch A, Radlwimmer B, Schramm J, Wiestler OD, Lichter P, Reifenberger G: Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene; 2007 Feb 15;26(7):1088-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The molecular pathogenesis of pleomorphic xanthoastrocytoma (PXA), a rare astrocytic brain tumor with a relatively favorable prognosis, is still poorly understood.
  • Interphase fluorescence in situ hybridization to tissue sections confirmed the presence of tumor cells with homozygous 9p21.3 deletions.
  • [MeSH-major] Astrocytoma / genetics. Chromosome Deletion. Chromosomes, Human, Pair 9 / genetics. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Gene Deletion. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins / deficiency

  • Genetic Alliance. consumer health - Chromosome 9.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909113.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN2B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein
  •  go-up   go-down


25. Lin ZX, Yang LJ, Huang Q, Fu J: Activated vascular endothelia regulate invasion of glioma cells through expression of fibronectin. Chin Med J (Engl); 2010 Jul;123(13):1754-61
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Previous researches have indicated that glioma invasion may occur within a tumor-host microecology, and that fibronectin may be involved in glioma invasion as an important component of the extracellular matrix.
  • However, how the interaction between tumor cells and vascular endothelial cells affects glioma invasion is poorly understood.
  • The aim of this study was to investigate the effects of the interaction between tumor cells and vascular endothelial cells on glioma invasion, and the relationship of this interaction to fibronectin.
  • METHODS: The localization of fibronectin in different brain astrocytoma tissues was determined by immunohistochemistry.
  • Additionally, the influence of the interaction between tumor cells and vascular endothelial cells on glioma cell invasion was determined by an in vitro rapid invasion test.
  • RESULTS: In brain astrocytoma tissues, fibronectin was present on the endothelial cells, in the extracellular matrix.
  • [MeSH-minor] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Cell Movement / physiology. Cells, Cultured. Coculture Techniques. Enzyme-Linked Immunosorbent Assay. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20819642.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Fibronectins
  •  go-up   go-down


26. Hlobilkova A, Ehrmann J, Knizetova P, Krejci V, Kalita O, Kolar Z: Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. Neoplasma; 2009;56(4):284-90
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression.
  • Astrocytomas, particularly high grade astrocytoma, are brain tumors with potent angiogenic activity.
  • Our immnunohistochemical study assessed vascular endothelial growth factor (VEGF), VEGF receptors (Flk-1, and Flt-1), the intermediate filamental protein nestin which plays a role in central nervous system development, and MMP-9, which belongs the family of matrix metalloproteinases implicated in tumor invasion and angiogenesis regulation.
  • We investigated the expression of VEGF, its receptors, nestin and MMP-9 in astrocytomas and their correlation with tumor grade.
  • Expression of Flt-1 and Flk-1 showed no significant differences between low and high grade tumor groups.
  • Nestin expression in tumor astrocytes and endothelial cells increased in high grade group (p same 0.007 and 0.003).
  • Expression of nestin and MMP-9 also suggest their likely role in astrocytoma vascular development and proliferation.
  • [MeSH-major] Astrocytoma / etiology. Brain Neoplasms / etiology. Intermediate Filament Proteins / metabolism. Matrix Metalloproteinase 9 / metabolism. Nerve Tissue Proteins / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473053.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


27. Shibahara I, Kanamori M, Kumabe T, Endo H, Sonoda Y, Ogawa Y, Watanabe M, Tominaga T: Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma. Brain Tumor Pathol; 2009;26(1):1-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma.
  • The incidence of hemorrhagic onset in pilocytic astrocytoma and pilomyxoid astrocytoma, and the clinical and histological characteristics, were compared to other types of neuroepithelial tumors or nonhemorrhagic pilocytic astrocytoma by retrospective review of 445 consecutive neuroepithelial tumors treated at our institute.
  • Hemorrhagic onset was observed in 4 of 35 (11.4%) patients with pilocytic astrocytoma and pilomyxoid astrocytoma, with higher incidence than in glioblastoma (3.9%), anaplastic oligodendroglioma (7.7%), and anaplastic ependymoma (7.1%).
  • The hemorrhagic onset occurred in 2 patients with sporadic pilocytic astrocytoma, 1 with pilocytic astrocytoma associated with neurofibromatosis type 1, and 1 with pilomyxoid astrocytoma.
  • There was no correlation between hemorrhagic onset and clinical features, including age, sex, tumor location, proliferative activity, or microvascular proliferation.
  • Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma is not as uncommon as was previously thought, so pilocytic astrocytoma or pilomyxoid astrocytoma should be considered in the differential diagnosis of patients with brain tumors manifesting as hemorrhagic onset.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Intracranial Hemorrhages / etiology. Intracranial Hemorrhages / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Capillaries / pathology. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Neurofibromatosis 1 / complications. Neurofibromatosis 1 / pathology. Paralysis / etiology. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408090.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


28. Faria AV, Azevedo GC, Zanardi VA, Ghizoni E, Queiroz LS: Dissemination patterns of pilocytic astrocytoma. Clin Neurol Neurosurg; 2006 Sep;108(6):568-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissemination patterns of pilocytic astrocytoma.
  • Two patients with multifocal pilocytic astrocytoma diagnosed by magnetic resonance imaging (MRI) and confirmed by histopathological examination are reported.
  • They presented distinct sites and mechanisms of metastasis: to distant ventricles through the cerebral spinal fluid (CSF) in patient 1 and to contralateral parenchyma, possibly through white matter tracts, in patient 2, a pathway not so far reported in pilocytic astrocytoma.
  • Early detection of multifocal pilocytic astrocytoma by MRI may change treatment strategies and improve prognosis.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology


29. Yue WY, Chen ZP: Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem; 2005 Aug;53(8):997-1002
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does vasculogenic mimicry exist in astrocytoma?
  • Vasculogenic mimicry (VM) has been observed in melanoma and in some nonmelanoma tumor types.
  • It is unknown whether a similar VM phenomenon exists in astrocytoma.
  • The results demonstrated that endothelium-lined vessels dominated the tumor microvasculature and stained positively for PAS, laminin, and endothelial marker.
  • Channels stained positively for PAS, laminin, and negatively for CD34 of the VM entrapped in the tumor tissue.
  • Furthermore, in astrocytoma, especially glioblastoma, focus of anaplastic tumor cells appeared with CD34 expression, whereas some tumor cells lost glial fibrillary acid protein expression.
  • It is assumed that genetically deregulated tumor cells in astrocytoma could lose the astrocyte-specific protein and express inappropriate markers not expected in cells of astrocyte lineage.
  • The present results suggest that VM phenomenon exists in some malignant astrocytoma.
  • [MeSH-major] Astrocytoma / blood supply. Brain Neoplasms / blood supply
  • [MeSH-minor] Antigens, CD34 / metabolism. Biomarkers / metabolism. Coloring Agents. Endothelium, Vascular / metabolism. Humans. Microcirculation. Neoplasm Staging. Periodic Acid. Schiff Bases

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923371.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Coloring Agents; 0 / Schiff Bases; 10450-60-9 / Periodic Acid
  •  go-up   go-down


30. Khan MA, Hashmi S: Low-grade astrocytoma causing calvarial scalloping. Pediatr Neurosurg; 2007;43(2):155-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade astrocytoma causing calvarial scalloping.
  • They are usually located deep within the skull and extend into the basal ganglia, though some are found near the surface of the brain.
  • Only 1 case of low-grade astrocytoma causing calvarial erosion has been reported in the literature of the CT era.
  • We report the first case of a low-grade astrocytoma causing calvarial erosion in an adolescent.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / surgery. Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Osteolysis / pathology. Osteolysis / surgery. Parietal Lobe / pathology. Parietal Lobe / surgery. Skull / pathology. Skull / surgery
  • [MeSH-minor] Adolescent. Bone Remodeling / physiology. Craniotomy. Diagnosis, Differential. Epilepsy, Generalized / etiology. Follow-Up Studies. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17337932.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


31. Habek M, Brinar VV, Mubrin Z, Barun B, Zarković K: Bilateral thalamic astrocytoma. J Neurooncol; 2007 Sep;84(2):175-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral thalamic astrocytoma.
  • Brain MRI revealed tumor mass in both thalami and according to WHO classification, the tumor corresponded to diffuse fibrillary astrocytoma grade II.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Thalamus / pathology
  • [MeSH-minor] Aged. Alzheimer Disease / pathology. Dementia / etiology. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522784.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


32. Pakos EE, Tsekeris PG, Chatzidimou K, Goussia AC, Markoula S, Argyropoulou MI, Pitouli EG, Konitsiotis S: Astrocytoma-like multiple sclerosis. Clin Neurol Neurosurg; 2005 Feb;107(2):152-7
MedlinePlus Health Information. consumer health - Multiple Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Astrocytoma-like multiple sclerosis.
  • Multiple sclerosis (MS) may sometimes mimic clinically and radiologically a brain tumor.
  • However, even in patients who underwent surgery, the appropriate preparation of the specimen is of crucial importance for the correct pathological diagnosis since tumors and non-neoplastic demyelinating lesions share some common histopathological features.
  • We present such a case of multiple sclerosis presenting with features of an astrocytoma and was treated with surgery and additional radiotherapy.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Multiple Sclerosis / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Neurol Neurosurg. 2005 Oct;107(6):535 [15925441.001]
  • (PMID = 15708234.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Burkhardt K, Heuberger F, Delavelle J: Pilocytic astrocytoma in the elderly. Clin Neuropathol; 2007 Nov-Dec;26(6):306-10
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilocytic astrocytoma in the elderly.
  • Pilocytic astrocytoma (WHO Grade 1) is a low-grade glioma with a favorable prognosis most commonly diagnosed in patients aged below 20.
  • We report the highly unusual case of an 85-year-old man whose neurological signs included Parkinsonism, and in whom post mortem examination revealed a pilocytic astrocytoma of the brainstem.
  • We also discuss the clinical, neuroradiological and neuropathological differential diagnosis.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Stem Neoplasms / diagnosis
  • [MeSH-minor] Age Factors. Aged, 80 and over. Diagnosis. Diagnosis, Differential. Humans. Male. Parkinson Disease / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18232598.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Stupp R, Reni M, Gatta G, Mazza E, Vecht C: Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol; 2007 Jul;63(1):72-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma in adults.
  • Anaplastic astrocytoma is an uncommon disease in the adult population.
  • Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Clinical Trials, Phase II as Topic. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prognosis. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for anaplastic astrocytoma .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478095.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 69
  •  go-up   go-down


35. Azad A, Deb S, Cher L: Primary anaplastic pilocytic astrocytoma. J Clin Neurosci; 2009 Dec;16(12):1704-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary anaplastic pilocytic astrocytoma.
  • We report two adult patients with pilocytic astrocytomas with anaplastic features at initial diagnosis.
  • Initial presentation of a pilocytic astrocytoma with anaplastic features is particularly uncommon and making a definitive diagnosis of pilocytic astrocytoma with anaplastic features can be challenging.
  • It is critical to differentiate glioblastoma (World Health Organization [WHO] grade 4) and pilocytic astrocytoma with anaplastic features (WHO grade 3) from pilocytic astrocytoma (WHO grade 1) as there are significant therapeutic and prognostic implications.
  • [MeSH-major] Anaplasia / complications. Astrocytoma / complications. Brain Neoplasms / complications

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815416.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


36. Fernandez A, Karavitaki N, Ansorge O, Fazal-Sanderson V, Wass JA: Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? Pituitary; 2008;11(3):325-30
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?
  • Insulin-like growth factor type I (IGF-I) is an important promoter in the tumorigenesis of several extracranial and intracranial neoplasms.
  • In astrocytic-cell tumors, the role of autocrine and paracrine IGF-I expression in enhancing tumoral progression is well established.
  • However, the influence of systemic IGF-I levels on the clinical behavior of astrocytic neoplasms remains an open subject of research.
  • We report the case of a 28-year-old man who presented simultaneously with acromegaly and an anaplastic astrocytoma, which had rapidly progressed from a low-grade astrocytoma.
  • The coexistence of systemic IGF-I hypersecretion with a quick progression in the histopathological grade of the astrocytoma raises the compelling question of whether the clinical behavior of the astrocytic tumor was influenced by the acromegalic status.
  • The role of IGF-I signaling in the pathogenesis of astrocytic-cell tumors and the experience with therapeutic strategies addressing this pathway in astrocytomas are also discussed.
  • [MeSH-major] Acromegaly / complications. Astrocytoma / complications. Brain Neoplasms / complications
  • [MeSH-minor] Adult. Cranial Irradiation. Craniotomy. Disease Progression. Ergolines / therapeutic use. Humans. Insulin-Like Growth Factor I / metabolism. Magnetic Resonance Imaging. Male. Neoplasm Staging. Peptides, Cyclic / therapeutic use. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Treatment Outcome. Up-Regulation

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18000757.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ergolines; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; LL60K9J05T / cabergoline
  •  go-up   go-down


37. Matsuda K, Sakurada K, Mouri W, Saino M, Sato S, Saito S, Kayama T, Nakazato Y: [Operative case of isomorphic astrocytoma]. Brain Nerve; 2007 Aug;59(8):881-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Operative case of isomorphic astrocytoma].
  • Recently, a subtype presenting with better prognosis has been proposed, and it is known as "isomorphic astrocytoma."
  • The tumor was resected under awake surgery.
  • The pathological diagnosis was diffuse astrocytoma, but this tumor was considered to be the isomorphic subtype.
  • Some parts of the tumor showed a relatively high MIB-1 labeling index (LI) of 9.2%, and additional 50-Gy radiotherapy was performed.
  • Isomorphic astrocytoma is characterized by prolonged epileptic seizures, a low MIB-1 LI, and better prognosis.
  • In our case, since the MIB-1 LI was higher in some parts of the tumor, the appropriate therapy for WHO Grade II tumors was performed.
  • However, this case was considered representative of isomorphic astrocytoma.
  • No reports of this tumor subtype have been previously described in Japan.
  • Therefore, this report is the first case of isomorphic astrocytoma reported to Japanese literature.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713125.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C: Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol; 2009 Sep;118(3):401-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
  • Separation of pilocytic astrocytoma from diffuse astrocytomas frequently poses problems mostly related to small sample size.
  • Precise classification and grading are essential due to different therapeutic strategies prompted by diagnoses of pilocytic astrocytoma WHO grade I, diffuse astrocytomas WHO grade II or anaplastic astrocytoma WHO grade III.
  • Thus, combined molecular analysis of BRAF and IDH1 is a sensitive and highly specific approach to separate pilocytic astrocytoma from diffuse astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Isocitrate Dehydrogenase / genetics. Proto-Oncogene Proteins B-raf / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Tissue Array Analysis


39. Niculescu CE, Stănescu L, Popescu M, Niculescu D: Supratentorial pilocytic astrocytoma in children. Rom J Morphol Embryol; 2010;51(3):577-80
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial pilocytic astrocytoma in children.
  • Brain tumors hold second place in tumoral pediatric pathology and have a complex etiopathogeny.
  • The authors describe the case of a child aged 2 years and 4 months with increased intracranial pressure, symptomatology accompanied by rapid deterioration of general condition.
  • Histopathological examination revealed the typical grade I pilocytic astrocytoma.
  • Time of diagnosis and surgical intervention is essential for further evolution and prognosis.
  • [MeSH-major] Astrocytoma / pathology. Supratentorial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20809042.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


40. Gong Y, Zhang Z: CellFrame: a data structure for abstraction of cell biology experiments and construction of perturbation networks. Ann N Y Acad Sci; 2007 Dec;1115:249-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have implemented an initial version of CellFrame, which contains data collected from reported experiments on human brain astrocytoma and colorectal cancer cell lines (http://cellframe.bioknowledge.org).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925354.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteome
  •  go-up   go-down


41. Shin E, Ki Chung C, Park SH: Granular cell astrocytoma. Pathol Res Pract; 2007;203(1):57-62
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell astrocytoma.
  • Granular cell astrocytoma (GCA) is a rare morphologic variant of astrocytomas, characterized by a prominent component of plump granular tumor cells.
  • It has an aggressive clinical course as compared with conventional astrocytoma of the same grade.
  • As its cytologic feature resembles that of a foamy histiocyte and, histologically, the tumor is rich in arborizing capillaries, it can be difficult to distinguish GCA from non-neoplastic diseases such as infarct or demyelinating disease.
  • Histopathology and immunohistochemical phenotype of this tumor were identical to the previous reports.
  • Ultrastructurally, secondary lysosome (so-called lipofuscin bodies) granules were present but not numerous; instead, many mitochondria and unusual paracrystalline inclusions were found in each tumor cell.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Inclusion Bodies / ultrastructure. Lipofuscin. Lysosomes / ultrastructure. Microscopy, Electron, Transmission. Mitochondria / ultrastructure. Pregnancy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197117.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lipofuscin
  •  go-up   go-down


42. Shi Y, Morgenstern N: Granular cell astrocytoma. Arch Pathol Lab Med; 2008 Dec;132(12):1946-50
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell astrocytoma.
  • Granular cell astrocytoma (GCA) is a rare type of malignant brain tumor with distinct morphologic features and aggressive clinical behavior.
  • Almost all GCAs occur in the cerebral hemispheres.
  • The tumor cells are usually positive for glial fibrillary acidic protein, S100, CD68, and epithelial membrane antigen.
  • The most important differential diagnoses include a number of reactive lesions such as cerebral infarction, multiple sclerosis, and progressive multifocal leukoencephalopathy.
  • Loss of 9p and 10q were identified in almost all cases of GCA, but they are not specific for this tumor.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Granular Cell Tumor / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Astrocytes / metabolism. Astrocytes / pathology. Diagnosis, Differential. Glial Fibrillary Acidic Protein / metabolism. Humans. Middle Aged. S100 Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19061297.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins
  • [Number-of-references] 22
  •  go-up   go-down


43. Darwish B, Arbuckle S, Kellie S, Besser M, Chaseling R: Desmoplastic infantile ganglioglioma/astrocytoma with cerebrospinal metastasis. J Clin Neurosci; 2007 May;14(5):498-501
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic infantile ganglioglioma/astrocytoma with cerebrospinal metastasis.
  • Desmoplastic infantile ganglioglioma and astrocytoma (DIG/DIA) are rare intracranial tumours of early childhood that involve superficial cerebral cortex and leptomeninges.
  • Despite the large size of the tumour and the presence of poorly differentiated cells, it is believed that the prognosis of DIG/DIA is excellent.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Spinal Neoplasms / secondary


44. Addo-Yobo SO, Straessle J, Anwar A, Donson AM, Kleinschmidt-Demasters BK, Foreman NK: Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma. J Neuropathol Exp Neurol; 2006 Aug;65(8):769-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma.
  • Pilocytic astrocytoma (PA) is the most common glioma of childhood.
  • To identify alternative targets of gefitinib in PA, we studied other members of the ErbB receptor tyrosine kinase family that have been identified in brain tumors.
  • Using gene expression microarray and Western blot analyses, we found that ErbB3 is highly overexpressed in PA compared with other pediatric brain tumors (glioblastoma, ependymoma, medulloblastoma, atypical teratoid/rhabdoid tumor, and choroid plexus papilloma).
  • Investigation of Sox10 in PA revealed that it is highly overexpressed relative to other pediatric brain tumors, lending support to the theory that Sox10-regulated overexpression of ErbB3 may be driving growth in PA.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. DNA-Binding Proteins / genetics. Gene Expression Regulation, Neoplastic / genetics. High Mobility Group Proteins / genetics. Receptor, ErbB-3 / genetics. Transcription Factors / genetics


45. Zhao YC, Li NY, Zhou XJ, Zhou HB, Ma HH, Zhang RS: [Clinicopathologic study of pilocytic astrocytoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Sep;37(9):609-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of pilocytic astrocytoma].
  • OBJECTIVE: To study clinicopathologic features, treatment and prognosis of pilocytic astrocytoma (PA).
  • Cystic degeneration was noted in 41 cases (60.3%), and enhancement of the tumor was noted in 43 cases (87.8%).
  • Total tumor excision was performed in 35 patients, subtotal tumor excision was performed in 31 patients, and the procedures of other 2 patients were not clear.
  • Among 51 patients with follow-up information, 44 were alive, 7 had recurrent tumor, and 7 died.
  • All cases showed diffuse positive staining for GFAP and low expression for Ki-67, except 1 anaplastic tumor with 10% Ki-67 indices.
  • CONCLUSIONS: PA is a benign, WHO grade I tumor with favorable prognosis, and does not require radiotherapy after total resection.
  • The tumor can be mistaken as higher-grade astrocytoma when involving the subarachnoid space, and with cytological atypia, leading to unnecessary radiotherapy after surgery.
  • The outcome for patients with brainstem tumor or anaplastic PA is poor.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Glial Fibrillary Acidic Protein / genetics. Recurrence

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094585.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


46. Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H, Park K, Hannon GJ, Yuan J, Louis DN, DePinho RA, Chin L: Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev; 2007 Jan 1;21(1):98-111
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma (GBM) is an astrocytic brain tumor characterized by an aggressive clinical course and intense resistance to all therapeutic modalities.
  • Enforced Bcl2L12 expression confers marked apoptosis resistance in primary cortical astrocytes, and, conversely, its RNA interference (RNAi)-mediated knockdown sensitizes human glioma cell lines toward apoptosis in vitro and impairs tumor growth with increased intratumoral apoptosis in vivo.
  • Thus, Bcl2L12 contributes to the classical tumor biological features of GBM such as intense apoptosis resistance and florid necrosis, and may provide a target for enhanced therapeutic responsiveness of this lethal cancer.

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1157-68 [11753564.001]
  • [Cites] Cell Death Differ. 2001 Apr;8(4):403-10 [11550092.001]
  • [Cites] Exp Hematol. 2002 Jun;30(6):503-12 [12063017.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):191-5 [12110890.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3 [12182418.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] J Neurochem. 2003 Jan;84(2):273-81 [12558990.001]
  • [Cites] Thromb Haemost. 2003 Jun;89(6):1081-8 [12783122.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1030-9 [14583630.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):25-35 [14749124.001]
  • [Cites] Cell. 2004 Feb 20;116(4):527-40 [14980220.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2757-65 [15077139.001]
  • [Cites] J Neurooncol. 2004 May;67(3):273-80 [15164982.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27320-6 [15140875.001]
  • [Cites] Biol Chem. 2004 Sep;385(9):779-83 [15493871.001]
  • [Cites] J Cell Biol. 1980 Jun;85(3):890-902 [6248568.001]
  • [Cites] Int J Cancer. 1993 Nov 11;55(5):760-4 [8244572.001]
  • [Cites] Neuropathol Appl Neurobiol. 1993 Oct;19(5):436-42 [8278027.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):352-61 [8625245.001]
  • [Cites] J Virol. 1996 Aug;70(8):5701-5 [8764092.001]
  • [Cites] J Exp Med. 1997 Apr 21;185(8):1481-6 [9126928.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5724-9 [9576951.001]
  • [Cites] J Exp Med. 1998 Sep 21;188(6):1185-90 [9743536.001]
  • [Cites] J Cell Biol. 1999 Jan 25;144(2):281-92 [9922454.001]
  • [Cites] Methods. 1999 Apr;17(4):313-9 [10196102.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22532-8 [10428830.001]
  • [Cites] J Neurosci. 2004 Nov 3;24(44):9977-84 [15525783.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11059-66 [15653686.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):287-97 [15803136.001]
  • [Cites] Genes Dev. 2006 Jan 1;20(1):1-15 [16391229.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):261-70 [16395408.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):18-23 [16397209.001]
  • [Cites] Science. 2006 Feb 10;311(5762):847-51 [16469926.001]
  • [Cites] Mol Cell. 2006 Aug;23(4):523-33 [16916640.001]
  • [Cites] Cancer Lett. 2007 Mar 8;247(1):48-55 [16647810.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):763-8 [10567494.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1241-7 [11062535.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Feb 23;281(2):322-7 [11181049.001]
  • [Cites] Bioessays. 2001 Feb;23(2):111-5 [11169582.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1162-70 [11221847.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2759-65 [11289159.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16059-63 [11274139.001]
  • [Cites] J Biochem. 2001 Jun;129(6):963-9 [11388913.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Genomics. 2001 Mar 1;72(2):217-21 [11401436.001]
  • [Cites] Cell Death Differ. 2001 Apr;8(4):335-44 [11550085.001]
  • [ErratumIn] Genes Dev. 2007 Feb 15;21(4):481
  • (PMID = 17210792.001).
  • [ISSN] 0890-9369
  • [Journal-full-title] Genes & development
  • [ISO-abbreviation] Genes Dev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA099041; United States / NCI NIH HHS / CA / P01 CA095616; United States / NINDS NIH HHS / NS / K08 NS042737; United States / NCI NIH HHS / CA / R01 CA57683; United States / NCI NIH HHS / CA / R01 CA057683; United States / NCI NIH HHS / CA / P01 CA95616; United States / NINDS NIH HHS / NS / K08NS42737
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosomes; 0 / BCL2L12 protein, human; 0 / Bcl2l2 protein, mouse; 0 / Immunoglobulin G; 0 / Muscle Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 7; EC 3.4.22.- / Caspase 9
  • [Other-IDs] NLM/ PMC1759904
  •  go-up   go-down


47. Tsuji K, Nakasu S, Tsuji A, Fukami T, Nozaki K: [Postoperative regression of desmoplastic infantile astrocytoma]. No Shinkei Geka; 2008 Nov;36(11):1035-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative regression of desmoplastic infantile astrocytoma].
  • Desmoplastic infantile astrocytoma/ganglioglioma (DIA/DIG) is a rare tumor that is usually located superficially with a large cystic component.
  • In rare cases, postoperative regression of the residual tumor has been reported.
  • A CT scan showed a large cystic tumor in his left parieto-occipital lobe.
  • The histopathological examination revealed an astrocytic tumor with marked desmoplasia.
  • In the central portion of the tumor, anaplastic features, such as necrosis, mitosis, and high nucleus-cytoplasmic ratio, were noticed.
  • Diagnosis was DIA.
  • Six months later when he was admitted for the second-stage surgery, MRI showed regression of the tumor.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery
  • [MeSH-minor] Gliosis. Humans. Infant. Male. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - Desmoplastic Infantile Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048924.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


48. Ranza E, Bertolotti A, Facoetti A, Mariotti L, Pasi F, Ottolenghi A, Nano R: Influence of imatinib mesylate on radiosensitivity of astrocytoma cells. Anticancer Res; 2009 Nov;29(11):4575-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of imatinib mesylate on radiosensitivity of astrocytoma cells.
  • Moreover, it is under investigation for the therapy of several other malignant tumours since protein kinases are frequently mutated or otherwise deregulated in human malignancies and they serve as a target for differentiating between tumour cells and normal tissues.
  • The objective of this study was to determine whether gamma radiation could sensitize astrocytoma cell lines to the effects of imatinib in vitro.
  • For this purpose, T98G and MOG-G-UVW astrocytoma cells were treated with imatinib alone or in combination with gamma radiation.
  • Imatinib confered greater radiosensitivity on the T98G tumour cells effecting a significant decrease in colony formation compared with radiation alone.
  • [MeSH-major] Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Piperazines / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Benzamides. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. Combined Modality Therapy. Dose-Response Relationship, Drug. Gamma Rays. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Imatinib Mesylate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032406.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


49. Li J, Zhang H, Wu J, Guan H, Yuan J, Huang Z, Li M: Prognostic significance of integrin-linked kinase1 overexpression in astrocytoma. Int J Cancer; 2010 Mar 15;126(6):1436-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of integrin-linked kinase1 overexpression in astrocytoma.
  • However, the clinical and functional significance of ILK1 expression has not been characterized previously in human astrocytoma.
  • In this study, we found that ILK1 was overexpressed, at both mRNA and protein levels, in astrocytoma cell lines as compared with normal human astrocytes.
  • The ILK1 mRNA and protein were significantly increased up to 5.6-fold and 10.1-fold, respectively, in primary astrocytoma in comparison with the paired adjacent noncancerous brain tissues obtained from the same patient.
  • Furthermore, immunohistochemical analysis revealed that ILK1 protein was positive in 208 of 228 (91.2%) paraffin-embedded archival astrocytoma specimens.
  • Statistical analysis suggested that the upregulation of ILK1 was significantly correlated with the histological grading of astrocytoma (p = 0.000), and that patients with high ILK1 level exhibited shorter survival time (p < 0.001).
  • Multivariate analysis revealed that ILK1 upregulation might be an independent prognostic indicator for the survival of patients with astrocytoma.
  • Taken together, our results suggest that ILK1 might represent a novel and useful prognostic marker for astrocytoma and play a role during the development and progression of the disease.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19676046.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.- / integrin-linked kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


50. Arai Y, Tsuchida T, Tanioka F, Sugimura H, Watanabe C, Hongo T, Tsutsui Y: Congenital anaplastic astrocytoma differentiated into pilocytic astrocytoma: an autopsy case. Neuropathology; 2008 Aug;28(4):433-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital anaplastic astrocytoma differentiated into pilocytic astrocytoma: an autopsy case.
  • We report an autopsy case of congenital astrocytoma and its histopathological changes during 5 years of the patient's development from birth to death.
  • At birth, a right exophthalmic tumor was observed, and MRI revealed that the tumor occupied the right orbital space and had also affected the suprasellar diencephalic structures.
  • The right orbital tumor, which was enucleated at 2 months of age, was a highly cellular tumor with moderate pleomorphism resembling anaplastic astrocytoma.
  • On the other hand, at autopsy, a brain tumor was found in the right diencephalic region with features of pilocytic astrocytoma, accompanied by leptomeningeal dissemination.
  • A biopsy specimen, which was obtained from the chiasmatic part of the tumor at 4 months of age, showed an intermediate appearance between the orbital tumor and the brain tumor obtained at autopsy.
  • Immunohistochemical examination confirmed that all three phases of the tumors showed an astrocytic lineage, and the Ki-67 labeling index decreased rapidly after 2 months of age.
  • We believe that this congenital anaplastic astrocytoma differentiated into a pilocytic astrocytoma during the 5 years of the patient's development.
  • The transformation of the congenital astrocytoma from anaplastic to pilocytic forms can be attributed to the nature of the tumor, namely postmitotic neoplastic cells are characterized by their ability to undergo self-differentiation, along with the organotropism of the developing brain.
  • [MeSH-major] Astrocytoma / congenital. Astrocytoma / pathology. Brain Neoplasms / congenital. Brain Neoplasms / pathology


51. Tanaka Y, Sasaki A, Ishiuchi S, Nakazato Y: Diversity of glial cell components in pilocytic astrocytoma. Neuropathology; 2008 Aug;28(4):399-407
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diversity of glial cell components in pilocytic astrocytoma.
  • To characterize the cellular density and proliferative activity of GFAP-negative cells in pilocytic astrocytoma (PA), surgically excised tissues of PAs (n=37) and diffuse astrocytomas (DAs) (n=11) were examined morphologically and immunohistochemically using antibodies against GFAP, Olig2, Iba1 and Ki-67 (MIB-1).
  • Semiquantitative analysis of Olig2 immunohistochemistry in microcystic areas might therefore be useful for the differential diagnosis of PA and DA.
  • [MeSH-major] Astrocytoma / metabolism. Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Nerve Tissue Proteins / biosynthesis. Neuroglia / metabolism
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. DNA-Binding Proteins / biosynthesis. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Infant, Newborn. Ki-67 Antigen / biosynthesis. Male. Middle Aged

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312545.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / AIF1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human
  •  go-up   go-down


52. Karmakar S, Banik NL, Patel SJ, Ray SK: 5-Aminolevulinic acid-based photodynamic therapy suppressed survival factors and activated proteases for apoptosis in human glioblastoma U87MG cells. Neurosci Lett; 2007 Mar 30;415(3):242-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma is the most common astrocytic brain tumor in humans.
  • We used 5-aminolevulinic acid (5-ALA) as a photosensitizer for PDT to induce apoptosis in human malignant glioblastoma U87MG cells and to understand the underlying molecular mechanisms.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histochem J. 1981 Jul;13(4):681-92 [6975767.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Photochem Photobiol. 1992 Jan;55(1):145-57 [1603846.001]
  • [Cites] Science. 1996 Nov 1;274(5288):782-4 [8864118.001]
  • [Cites] Biochem J. 1996 Nov 1;319 ( Pt 3):683-90 [8920967.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2282-308 [9191516.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):96-9 [9422513.001]
  • [Cites] J Biol Chem. 1998 Aug 28;273(35):22490-7 [9712874.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1680-3 [9733516.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):387, 389 [9989401.001]
  • [Cites] Arch Biochem Biophys. 2004 Dec 15;432(2):178-87 [15542056.001]
  • [Cites] Arch Biochem Biophys. 2005 Jan 15;433(2):435-46 [15581600.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):289-99 [15662970.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):6447-54 [15590628.001]
  • [Cites] Glia. 2005 Apr 15;50(2):160-7 [15685605.001]
  • [Cites] Biochim Biophys Acta. 2005 Feb 11;1722(1):43-50 [15716135.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1551-60 [15742333.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):516-28 [15827324.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11051-60 [16322255.001]
  • [Cites] Neuroscience. 2006 May 12;139(2):577-95 [16504408.001]
  • [Cites] Neuroscience. 2006 Sep 1;141(3):1265-80 [16765523.001]
  • [Cites] Apoptosis. 2006 Sep;11(9):1629-41 [16820963.001]
  • [Cites] Neurosci Lett. 2006 Oct 16;407(1):53-8 [16949208.001]
  • [Cites] J Neurochem. 2000 Apr;74(4):1646-55 [10737623.001]
  • [Cites] J Neurosci. 2000 Apr 15;20(8):2825-34 [10751434.001]
  • [Cites] FEBS Lett. 2000 Sep 1;480(2-3):193-6 [11034327.001]
  • [Cites] Cell Death Differ. 2000 Oct;7(10):866-7 [11279531.001]
  • [Cites] J Photochem Photobiol B. 2003 Feb;69(2):71-85 [12633980.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12(7):791-801 [12651874.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):14162-7 [12576481.001]
  • [Cites] J Photochem Photobiol B. 2004 Jan 23;73(1-2):67-78 [14732253.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2746-56 [15077138.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2785-96 [15077142.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] J Immunol. 1990 May 1;144(9):3326-33 [1691753.001]
  • (PMID = 17335970.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS057811-01A1; United States / NCI NIH HHS / CA / R01 CA091460-04; United States / NCI NIH HHS / CA / R01 CA091460; United States / NINDS NIH HHS / NS / R01 NS 57811; United States / NCI NIH HHS / CA / R01 CA 91460; United States / NINDS NIH HHS / NS / R01 NS057811
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Apoptosis Inducing Factor; 0 / Apoptosis Regulatory Proteins; 0 / BIRC3 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / NF-kappa B; 88755TAZ87 / Aminolevulinic Acid; EC 3.4.- / Peptide Hydrolases; EC 3.4.22.- / Calpain; EC 3.4.22.- / Caspases; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ NIHMS20981; NLM/ PMC2533742
  •  go-up   go-down


53. Chamberlain MC, Johnston S: Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol; 2009 Feb;91(3):359-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.
  • A retrospective study of bevacizumab only in adults with recurrent temozolomide (TMZ)-refractory anaplastic astrocytoma (AA) with a primary objective of determining progression free survival (PFS).
  • Time to tumor progression ranged from 1 to 20 months (median: 7).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / mortality. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953491.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


54. Sharma MK, Watson MA, Lyman M, Perry A, Aldape KD, Deák F, Gutmann DH: Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma. Neurology; 2006 Jan 10;66(1):127-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma.
  • Using whole genome expression microarray technology to discover clinically relevant biomarkers for pilocytic astrocytoma (PA), the authors identified matrilin-2 as a unique mRNA overexpressed in PA.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Extracellular Matrix Proteins / genetics. Glycoproteins / genetics

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16401863.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / Glycoproteins; 0 / MATN2 protein, human; 0 / Matrilin Proteins; 0 / RNA, Messenger
  •  go-up   go-down


55. See SJ, Ty A, Wong MC: Salvage chemotherapy in progressive high-grade astrocytoma. Ann Acad Med Singapore; 2007 May;36(5):343-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy in progressive high-grade astrocytoma.
  • INTRODUCTION: Despite aggressive multidisciplinary interventions, patients with high-grade astrocytomas experience tumour progression or recurrence.
  • MATERIALS AND METHODS: A retrospective review of relevant clinical and radiographic information of patients who received at least one cycle of salvage chemotherapy for progressive high-grade astrocytoma at the National Cancer Center, Singapore, from March 2004 to September 2006, was conducted.
  • Patients underwent regular assessment with clinical examination and magnetic resonance brain imaging to gauge response to salvage chemotherapy.
  • RESULTS: Twenty-four patients (13 glioblastomas, 11 anaplastic astrocytomas) had received chemotherapy as salvage treatment following progression of their high-grade astrocytoma.
  • Among 20 patients assessable for tumour response, there were 4 patients with partial responses and 9 with stable responses.
  • The 12-month survival rate for the entire group from time of onset of tumour progression was 49.6%.
  • For patients with anaplastic astrocytoma, the 12-month survival rate was 73%.
  • CONCLUSION: Durable disease control and prolonged survival were seen in a significant portion of selected patients with progressive high-grade astrocytoma who received salvage chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Glioblastoma / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies. Singapore. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549281.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


56. Rao SA, Santosh V, Somasundaram K: Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol; 2010 Oct;23(10):1404-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma.
  • Malignant astrocytoma includes anaplastic astrocytoma (grade III) and glioblastoma (grade IV).
  • Among them, glioblastoma is the most common primary brain tumor with dismal responses to all therapeutic modalities.
  • We performed a large-scale, genome-wide microRNA (miRNA) (n=756) expression profiling of 26 glioblastoma, 13 anaplastic astrocytoma and 7 normal brain samples with an aim to find deregulated miRNA in malignant astrocytoma.
  • We identified several differentially regulated miRNAs between these groups, which could differentiate glioma grades and normal brain as recognized by PCA.
  • More importantly, we identified a most discriminatory 23-miRNA expression signature, by using PAM, which precisely distinguished glioblastoma from anaplastic astrocytoma with an accuracy of 95%.
  • The differential expression pattern of nine miRNAs was further validated by real-time RT-PCR on an independent set of malignant astrocytomas (n=72) and normal samples (n=7).
  • Thus we have identified the miRNA expression signature for malignant astrocytoma, in particular glioblastoma, and showed the miRNA involvement and their importance in astrocytoma development.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. MicroRNAs / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20711171.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down


57. Linscott LL, Osborn AG, Blaser S, Castillo M, Hewlett RH, Wieselthaler N, Chin SS, Krakenes J, Hedlund GL, Sutton CL: Pilomyxoid astrocytoma: expanding the imaging spectrum. AJNR Am J Neuroradiol; 2008 Nov;29(10):1861-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid astrocytoma: expanding the imaging spectrum.
  • BACKGROUND AND PURPOSE: Pilomyxoid astrocytoma (PMA) is a recently described variant of pilocytic astrocytoma (PA) with unique clinical and histopathologic characteristics.
  • RESULTS: Patients ranged in age from 9 months to 46 years at initial diagnosis.
  • CONCLUSION: This series expands the clinical and imaging spectrum of PMA and identifies characteristics that should suggest consideration of this uncommon diagnosis.
  • PMA remains a histologic diagnosis without definitive imaging findings that distinguish it from PA.
  • [MeSH-major] Astrocytoma / classification. Astrocytoma / diagnosis. Brain Neoplasms / classification. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701580.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


58. Yoshida T, Niwa F, Kimura S, Nakagawa M: Anaplastic astrocytoma presenting as reversible posterior leukoencephalopathy syndrome. Neurologist; 2006 Nov;12(6):311-3
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma presenting as reversible posterior leukoencephalopathy syndrome.
  • We report a 60-year-old man with grade III astrocytoma, who presented with status epilepticus.
  • The initial MRI did not demonstrate typical findings of an astrocytoma but rather showed reversible posterior leukoencephalopathy syndrome (RPLS).
  • A brain tumor should be considered and the patient carefully followed by MRI, even if the MRI white matter lesion pattern suggests RPLS.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Diseases / diagnosis. Occipital Lobe / pathology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122727.001).
  • [ISSN] 1074-7931
  • [Journal-full-title] The neurologist
  • [ISO-abbreviation] Neurologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Shinohara Y, Kinoshita T, Kinoshita F, Moroi J, Yoshida Y, Nakazato Y: F-18 FDG-PET imaging of dysembryoplastic neuroepithelial tumor-like astrocytoma. Clin Nucl Med; 2009 Oct;34(10):700-2
Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG-PET imaging of dysembryoplastic neuroepithelial tumor-like astrocytoma.
  • Cerebral astrocytoma needs to be distinguished from dysembryoplastic neuroepithelial tumor (DNT) when a well-demarcated, cortically based and pseudo-cystic tumor with minimal mass effect is demonstrated on magnetic resonance imaging.
  • We report an unusual case of DNT-like astrocytoma.
  • 18F fluoro-deoxy-glucose (FDG) positron emission tomography showed a focal increase of FDG uptake in a deep part of the tumor.
  • Histologic examination revealed predominantly microcystic change with oligodendrocyte-like cells, leading to a diagnosis of DNT.
  • However, increased cellularity and nuclear atypia of astrocytes within the tumor were conspicuous as for DNT.
  • Four years after excision, tumor recurrence was detected.
  • FDG-positron emission tomography is useful for identifying the malignant potential of DNT-like astrocytoma.
  • [MeSH-major] Astrocytoma / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasms, Neuroepithelial / radionuclide imaging. Positron-Emission Tomography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893407.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


60. Cuellar-Baena S, Morales JM, Martinetto H, Calvar J, Sevlever G, Castellano G, Cerdá-Nicolás M, Celda B, Monleon D: Comparative metabolic profiling of paediatric ependymoma, medulloblastoma and pilocytic astrocytoma. Int J Mol Med; 2010 Dec;26(6):941-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative metabolic profiling of paediatric ependymoma, medulloblastoma and pilocytic astrocytoma.
  • Brain tumours are the most common solid tumours in children and a major cause of childhood mortality.
  • The most common paediatric brain tumours include ependymomas, cerebellar astrocytomas and medulloblastomas.
  • These brain tumours are highly heterogeneous regarding their histology, prognosis and therapeutic response.
  • Subtle biochemical changes can be detected in intact tissues by High-Resolution Proton Magnetic Angle Spinning Spectroscopy (HR-MAS) revealing the status of tumour microheterogeneity and metabolic alterations before they are morphologically detectable.
  • In this study, we present metabolic profiles by HR-MAS of 20 intact tissue samples from paediatric brain tumours.
  • Tumour types include ependymoma, medulloblastoma and pilocytic astrocytoma.
  • The metabolic characterization of paediatric brain tumour tissue by HR-MAS spectroscopy provided differential patterns for these tumours.
  • The metabolic composition of the tumour tissue was highly consistent with previous in vivo and ex vivo studies.
  • Some resonances detected in this work and not previously observed by in vivo spectroscopy also show potential in determining tumour type and grade (fatty acids, phenylalanine, glutamate).
  • Overall, this work suggests that the additional information obtained by NMR metabolic profiling applied to tissue from paediatric brain tumours may be useful for assessing tumour grade and determining optimum treatment strategies.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioma / metabolism. Metabolomics / methods
  • [MeSH-minor] Amino Acids / chemistry. Analysis of Variance. Brain Chemistry. Child. Child, Preschool. Fatty Acids / chemistry. Humans. Infant. Magnetic Resonance Imaging. Principal Component Analysis


61. Saka E, Ozkaynak S, Tuncer R: Tongue tremor in brainstem pilocytic astrocytoma. J Clin Neurosci; 2006 May;13(4):503-6
MedlinePlus Health Information. consumer health - Tremor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tongue tremor in brainstem pilocytic astrocytoma.
  • The patient was diagnosed with brainstem pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Stem Neoplasms / pathology. Tongue / physiopathology. Tremor / etiology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • Genetic Alliance. consumer health - Tremor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16678738.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


62. Hillmann P, Köse M, Söhl K, Müller CE: Ammonium-induced calcium mobilization in 1321N1 astrocytoma cells. Toxicol Appl Pharmacol; 2008 Feb 15;227(1):36-47
Hazardous Substances Data Bank. POTASSIUM CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ammonium-induced calcium mobilization in 1321N1 astrocytoma cells.
  • In the present study, an astrocytoma cell line 1321N1 and a neuroblastoma glioma hybrid cell line NG108-15 were used as model systems for astrocytes and neuronal cells, respectively.
  • Ammonium salts evoked a transient increase in intracellular calcium concentrations ([Ca(2+)](i)) in astrocytoma (EC(50)=6.38 mM), but not in NG108-15 cells.
  • Ammonium (5 mM) also significantly inhibited the proliferation of 1321N1 astrocytoma cells.
  • While mRNA for the mammalian ammonium transporters RhBG and RhCG could not be detected in 1321N1 astrocytoma cells, both transporters were expressed in NG108-15 cells.
  • RhBG and RhBC in brain may promote the excretion of NH(3)/NH(4)(+) from neuronal cells.
  • Human 1321N1 astrocytoma cells appear to be an excellent, easily accessible human model for studying HE, which can substitute animal studies, while NG108-15 cells may be useful for investigating the role of the recently discovered Rhesus family type ammonium transporters in neuronal cells.
  • Our findings may contribute to the understanding of pathologic ammonium effects in different brain cells, and to the treatment of hyperammonemia.
  • [MeSH-major] Astrocytoma / metabolism. Calcium / metabolism. Quaternary Ammonium Compounds / pharmacology
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. DNA Primers. Humans. Potassium Chloride / pharmacology. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061226.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Quaternary Ammonium Compounds; 660YQ98I10 / Potassium Chloride; SY7Q814VUP / Calcium
  •  go-up   go-down


63. Zhou W, Jiang Z, Song X, Liu Y, Wen P, Guo Y, Xu F, Kong L, Zhang P, Han A, Yu J: Promoter hypermethylation-mediated down-regulation of CXCL12 in human astrocytoma. J Neurosci Res; 2008 Oct;86(13):3002-10
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation-mediated down-regulation of CXCL12 in human astrocytoma.
  • However, the role of CXCL12/CXCR4 axis, especially CXCL12, in the regulation of tumor invasiveness is largely still unknown.
  • Using real-time quantitative RT-PCR assays, we observed that CXCR4 expression increased with increasing WHO grade in astrocytoma, suggesting that CXCR4 may be a marker of aggressive biological behavior of astrocytoma.
  • The expression levels of CXCL12 mRNA in glioblastomas (WHO grade IV) were significantly higher than in normal brain tissues.
  • In summary, our data show that CXCL12 promoter hypermethylation is an early event in astrocytoma development.
  • However, the high expressions of CXCR4 and CXCL12 in glioblastomas, the more invasive astrocytomas, suggest a different role of CXCL12/CXCR4 signaling axis in astrocytoma progression.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chemokine CXCL12 / genetics. DNA Methylation. Promoter Regions, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18512766.001).
  • [ISSN] 1097-4547
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / RNA, Messenger; 0 / Receptors, CXCR4
  •  go-up   go-down


64. Komotar RJ, Zacharia BE, Sughrue ME, Mocco J, Carson BS, Tihan T, Otten ML, Burger PC, Garvin JH, Khandji AG, Anderson RC: Magnetic resonance imaging characteristics of pilomyxoid astrocytoma. Neurol Res; 2008 Nov;30(9):945-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging characteristics of pilomyxoid astrocytoma.
  • OBJECTIVE: Pilomyxoid astrocytoma (PMA) is a recently identified pediatric low-grade neoplasm that was previously classified as pilocytic astrocytoma (PA), yet demonstrates unique histological features and more aggressive behavior.
  • Radiographic characteristics of the tumor were recorded in each case.
  • All tissue samples were independently reviewed for confirmation of pathologic diagnosis.
  • CONCLUSION: Pilomyxoid astrocytoma is a well-circumscribed pediatric neoplasm that commonly originates from the midline of the neuroaxis and lacks peritumoral edema or central necrosis.
  • It is critical to recognize the predominantly solid and well-circumscribed nature of the neoplasm to avoid confusion with an infiltrating astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Brain / pathology. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Infant. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18662499.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, Greenman J: Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep; 2006 Jun;15(6):1513-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients.
  • The balance between Th1 and Th2 cytokines is thought to be an important factor in terms of tumour prognosis.
  • Serum samples from 61 newly diagnosed patients with brain tumours and 50 age- and sex-matched non-tumour controls were analysed by ELISA for circulating levels of interleukin-12 (IL-12p70 and p40) and interleukin-10 (IL-10); pivotal Th1 and Th2 cytokines, respectively.
  • Patients were divided into various groups depending on their histological diagnosis: meningioma (n=11), anaplastic astrocytoma (n=4) and glioblastoma multiforme (GBM; n=46).
  • Significant reduction in serum IL-12 was seen in all groups as compared with the controls: meningioma, p=0.03; anaplastic astrocytoma, p<0.001; and GBM, p<0.001.
  • Conversely, serum IL-10 was significantly increased in anaplastic astrocytoma, p=0.02, and GBM, p=0.03.
  • This study shows that patients with advanced primary intracranial malignancies have decreased circulating IL-12 and increased circulating IL-10, demonstrating that brain tumours have a major systemic effect on the immune system.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-10 / blood. Interleukin-12 / blood. Meningioma / immunology. Th1 Cells / immunology. Th2 Cells / immunology


66. Kim SH, Lee KG, Kim TS: Cytologic characteristics of subependymal giant cell astrocytoma in squash smears: morphometric comparisons with gemistocytic astrocytoma and giant cell glioblastoma. Acta Cytol; 2007 May-Jun;51(3):375-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic characteristics of subependymal giant cell astrocytoma in squash smears: morphometric comparisons with gemistocytic astrocytoma and giant cell glioblastoma.
  • OBJECTIVE: To evaluate the squash smear features of subependymal giant cell astrocytoma (SEGA) in comparison with gemistocytic astrocytoma and giant cell glioblastoma.
  • STUDY DESIGN: We compared the squash smear features of 3 cases of SEGA, 9 cases of gemistocytic astrocytoma and 3 cases of giant cell glioblastoma with the morphometric findings.
  • While the gemistocytic astrocytoma had several tumor cells showing a vertically located nucleus, the tumor cells of SEGA showed nuclei oriented mainly in parallel.
  • CONCLUSION: These squash cytologic features of SEGA can be very helpful in the differential diagnosis by excluding mimics.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Nucleus / pathology. Child. Child, Preschool. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Male


67. Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G, Lu D: Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res; 2006 Dec;56(4):450-8
Hazardous Substances Data Bank. SODIUM SULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma.
  • LATS1 and LATS2 are tumor suppressor genes implicated in the regulation of cell cycle, but their methylation statuses are still unknown in human astrocytoma.
  • But no methylation of LATS1 and LATS2 promoter was detected in the 10 normal brain tissues.
  • There was an increased methylation frequency of LATS1 and LATS2 with the malignant development of astrcytoma.
  • Our results suggested that LATS1 and LATS2 mRNA was down-regulated in astrocytoma by hypermethylation of the promoter.
  • The methylation and mRNA expression of LATS1 and LATS2 may provide useful clues to the development of the diagnostic assays for astrocytoma.
  • Our results also suggested that LATS1 and LATS2 may be a useful target for astrocytoma therapy.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Promoter Regions, Genetic / genetics. Protein-Serine-Threonine Kinases / biosynthesis. Tumor Suppressor Proteins / biosynthesis
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / pharmacology. Apoptosis / drug effects. Azacitidine / pharmacology. Cell Line, Tumor. DNA / biosynthesis. DNA / genetics. Dealkylation. Down-Regulation. Female. Flow Cytometry. Humans. Male. Methylation. Middle Aged. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Sulfates / pharmacology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17049657.001).
  • [ISSN] 0168-0102
  • [Journal-full-title] Neuroscience research
  • [ISO-abbreviation] Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / RNA, Messenger; 0 / Sulfates; 0 / Tumor Suppressor Proteins; 0YPR65R21J / sodium sulfate; 9007-49-2 / DNA; EC 2.7.1.- / LATS1 protein, human; EC 2.7.1.11 / LATS2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; M801H13NRU / Azacitidine
  •  go-up   go-down


68. Omura T, Nawashiro H, Osada H, Shima K, Tsuda H, Shinsuke A: Pilomyxoid astrocytoma of the fourth ventricle in an adult. Acta Neurochir (Wien); 2008 Nov;150(11):1203-6; discussion 1206

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid astrocytoma of the fourth ventricle in an adult.
  • Pilomyxoid astrocytomas have been identified as a variant of pilocytic astrocytoma.
  • This tumour corresponds to a WHO grade II neoplasm whereas pilocytic astrocytoma corresponds to WHO grade I.
  • We have encountered an infratentorial tumour with pilomyxoid features in an adult.
  • Brain MRI revealed a mass occupying the fourth ventricle.
  • Additional knowledge and recognition of this entity is necessary to improve treatment of pilomyxoid astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology. Fourth Ventricle / pathology
  • [MeSH-minor] Adult. Age Distribution. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / physiopathology. Humans. Hyperacusis / etiology. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Tinnitus / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958385.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


69. Aguilar Moliner I, Costa Orvay JA, Juma K, Costa Clara JM, Cruz Martínez O, Pou Fernández J: [Optic pathway astrocytoma: an unusual cause of failure to thrive in infants]. An Pediatr (Barc); 2007 Jun;66(6):622-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optic pathway astrocytoma: an unusual cause of failure to thrive in infants].
  • [Transliterated title] Astrocitoma de vías ópticas: una causa infrecuente de retraso ponderal en el lactante.
  • We report a case of low-grade astrocytoma of the optic pathway in a 2-month-old child whose main symptoms at diagnosis were failure to thrive and anorexia.
  • Unfortunately, despite therapeutic efforts, the tumor showed local and metastatic progression refractory to chemotherapy.
  • The patient died 3 months after diagnosis.
  • We conclude that diencephalic tumors must be considered in the differential diagnosis of failure to thrive during the first year of life, especially when, after initial investigations, a cause is not found.
  • [MeSH-major] Brain Neoplasms / diagnosis. Failure to Thrive / etiology. Optic Nerve Glioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583627.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


70. Abe T, Inoue R, Isono M, Ishii K, Fujiki M, Kamida T, Kobayashi H, Kashima K, Kusakabe T, Nakazato Y: Benign pleomorphic astrocytoma in the hypothalamus--case report. Neurol Med Chir (Tokyo); 2006 Feb;46(2):101-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign pleomorphic astrocytoma in the hypothalamus--case report.
  • A 41-year-old woman presented with an unusual case of benign astrocytoma with marked pleomorphism manifesting as consciousness disturbance due to intraventricular hemorrhage.
  • Despite partial resection of the tumor without additional therapy, there have been no signs of tumor regrowth for 6 years.
  • The histological findings revealed solid proliferation of tumor cells with marked pleomorphism, contrary to the benign clinical course.
  • Immunohistochemical staining indicated the glial origin of the tumor.
  • The tumor was similar to pleomorphic xanthoastrocytoma, but the histological findings were not exactly identical, indicating a new histological entity.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Hypothalamus / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498222.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


71. Komotar RJ, Mocco J, Jones JE, Zacharia BE, Tihan T, Feldstein NA, Anderson RC: Pilomyxoid astrocytoma: diagnosis, prognosis, and management. Neurosurg Focus; 2005 Jun 15;18(6A):E7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid astrocytoma: diagnosis, prognosis, and management.
  • Pilomyxoid astrocytoma (PMA) is a recently defined pediatric brain tumor; PMAs were previously classified within the pilocytic astrocytoma (PA) category.
  • To increase awareness of PMA within the neurosurgical community, the authors review the diagnostic criteria, prognostic implications, and current management of this recently described pediatric low-grade astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurg Focus. 2007;23(5):E2 [18004964.001]
  • (PMID = 16048293.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


72. Zhang L, Zhang WP, Hu H, Wang ML, Sheng WW, Yao HT, Ding W, Chen Z, Wei EQ: Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology; 2006 Apr;26(2):99-106
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma.
  • The levels of leukotrienes increase after brain injury and when tumors are present.
  • It has been reported that 5-LOX is widely expressed in the brain and that 5-LOX inhibition provides neuroprotection.
  • However, there is still no information available for the expression patterns of 5-LOX in human brain following trauma or with astrocytomas.
  • In traumatic brain injury, 5-LOX expression increased in glial cells and neutrophils.
  • No 5-LOX expression was found in brain microvessel endothelia, except in the regenerated endothelia of a patient 8 days following brain trauma.
  • Furthermore, 5-LOX expression increased and showed a granular pattern in high-grade (grade III/IV) astrocytoma.
  • These results indicate that 5-LOX has multiple expression patterns, and can be induced by brain injury, which implies that 5-LOX might have pathophysiological roles in the human brain.
  • [MeSH-major] Arachidonate 5-Lipoxygenase / biosynthesis. Astrocytoma / metabolism. Brain / metabolism. Brain Injuries / metabolism. Brain Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708542.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  •  go-up   go-down


73. Li HM, Hsu SS, Wang JS, Weng MJ, Fu JH, Chen CK, Lai PH: Cerebral pilocytic astrocytoma with spontaneous intracranial hemorrhage in adults. J Chin Med Assoc; 2008 Nov;71(11):587-93
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral pilocytic astrocytoma with spontaneous intracranial hemorrhage in adults.
  • We report 2 cases of adult pilocytic astrocytoma with intracranial hemorrhage.
  • Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a well-enhanced and circumscribed cystic hemorrhagic tumor with mural nodule over the cerebral hemisphere region.
  • The measured relative cerebral blood volume ratios of the mural nodules in these 2 cases were, respectively, 1.34 and 2.81 when compared with normal white matter.
  • Since pilocytic astrocytoma and other cystic tumors with mural nodule (such as hemangioblastoma) have similar findings on conventional CT and MRI, PWI is helpful in the differential diagnosis.
  • The literature on hemorrhagic pilocytic astrocytoma is also reviewed.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Cerebral Hemorrhage / etiology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015059.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


74. Shimizu H, Mori O, Ohaki Y, Kamoi S, Kobayashi S, Okada S, Maeda S, Naito Z: Cytological interface of diffusely infiltrating astrocytoma and its marginal tissue. Brain Tumor Pathol; 2005;22(2):59-74
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological interface of diffusely infiltrating astrocytoma and its marginal tissue.
  • Cytological differences between infiltrating lesions of the diffusely infiltrating astrocytoma (DIA) and reactive gliosis at its periphery have not yet been established.
  • We compared histological specimens from cytological crush preparations of 200 brain tumors to characterize the cytology of the DIA and to discriminate it from reactive gliosis.
  • First, the cytological findings of the backgland brain parenchyma were assessed.
  • Second, we looked at the nuclear characteristics of the DIA, comparing them with those of other brain tumors.
  • Third, the cytology of the infiltrating DIA was assessed together with brain parenchymal elements.
  • The cytological findings of this area are important because the surgeon may have to make a rapid diagnosis regarding the existence of the tumor.
  • [MeSH-major] Astrocytoma / pathology. Brain / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Gliosis / pathology
  • [MeSH-minor] Adult. Astrocytes / ultrastructure. Axons / ultrastructure. Biopsy. Carcinoma / secondary. Cell Nucleus / ultrastructure. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Myelin Sheath / ultrastructure. Neoplasm Invasiveness. Neurons / ultrastructure. Oligodendroglia / ultrastructure. Staining and Labeling / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095107.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Watanabe T, Katayama Y, Yoshino A, Yachi K, Ohta T, Ogino A, Komine C, Fukushima T: Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol; 2007 Jan;17(1):5-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression.
  • The aim of the present study was to elucidate genetic alterations that are critically involved in astrocytoma progression.
  • We characterized 27 World Health Organization grade II fibrillary astrocytomas which later underwent recurrence or progression, paying specific attention to the CpG island methylation status of critical growth regulatory genes. p14(ARF) and O(6)-methylguanine-DNA methyltransferase (MGMT) hypermethylation represented frequent events (26% and 63%, respectively), which were mutually exclusive except in one case, with alternate or simultaneous methylation of these two genes occurring in 85% of our tumor series.
  • Examination of 20 cases whose histological data for recurrent tumors were available revealed that malignant progression occurred in all of the tumors with p14(ARF) methylation but less frequently (50%) in the lesions with MGMT methylation.
  • On analysis of their respective recurrent tumors, five of six patients whose primary low-grade tumors carried p14(ARF) methylation exhibited homozygous co-deletions of the p14(ARF), p15(INK4b) and p16(INK4a) genes, which were restricted to glioblastoma as the most malignant end point.
  • Our findings suggest that p14(ARF) hypermethylation and MGMT hypermethylation constitute distinct molecular pathways of astrocytoma progression, which could differ in biological behavior and clinical outcome.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. CpG Islands / physiology. Neoplasm Recurrence, Local / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Tumor Suppressor Protein p14ARF / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Methylation. Middle Aged. Mutation / genetics. Promoter Regions, Genetic / physiology. Survival Analysis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493032.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


76. Zhang W, Kawanishi M, Miyake K, Kagawa M, Kawai N, Murao K, Nishiyama A, Fei Z, Zhang X, Tamiya T: Association between YKL-40 and adult primary astrocytoma. Cancer; 2010 Jun 1;116(11):2688-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between YKL-40 and adult primary astrocytoma.
  • The objectives of this study were to explore YKL-40 protein expression status and World Health Organization (WHO) pathologic grades of primary human astrocytoma and to investigate the role of YKL-40 in the proliferation of both established and primary astrocytoma cells in vitro.
  • RESULTS: The percentage of positive cells and the staining intensity differed significantly between different pathologic tumor grades (P < .001).
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Glycoproteins / metabolism. Lectins / metabolism
  • [MeSH-minor] Adipokines. Adult. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Glioma / metabolism. Humans. Immunohistochemistry. MAP Kinase Signaling System. Male. Middle Aged. RNA, Small Interfering / pharmacology. Transfection


77. Chamberlain MC, Wei-Tsao DD, Blumenthal DT, Glantz MJ: Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer; 2008 May 1;112(9):2038-45
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
  • BACKGROUND: The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS).
  • The median time to tumor progression was 4.1 month.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361434.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


78. Song WS, Guo LB, Hong ZY, Li JJ, Wu J: [Serum S100 protein and radiation-induced brain injury in astrocytoma patients]. Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun;25(6):723-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serum S100 protein and radiation-induced brain injury in astrocytoma patients].
  • OBJECTIVE: To study the value of serum S100 protein in the diagnosis of radiation-induced brain injury in astrocytoma patients.
  • METHODS: Serum S100 protein levels were detected by enzyme-linked immunosorbent assay in 86 astrocytoma patients in the course of radiotherapy.
  • CONCLUSION: High levels of serum S100 protein are associated with radiation-induced brain injury in astrocytoma patients and may serve as the marker for early diagnosis of the injury.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Radiation Injuries / blood. S100 Proteins / blood
  • [MeSH-minor] Adult. Biomarkers / blood. Brain / radiation effects. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958321.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / S100 Proteins
  •  go-up   go-down


79. Beppu T, Sato Y, Uesugi N, Kuzu Y, Ogasawara K, Ogawa A: Desmoplastic infantile astrocytoma and characteristics of the accompanying cyst. Case report. J Neurosurg Pediatr; 2008 Feb;1(2):148-51
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic infantile astrocytoma and characteristics of the accompanying cyst. Case report.
  • A desmoplastic infantile astrocytoma (DIA) is an extremely rare tumor that comprises a solid astrocytic tumor accompanied by a large cyst and involves the superficial cerebral cortex and leptomeninges in infants.
  • The solid part of this type of tumor has been well described in various reports and books, but characteristics of the cystic portion have remained unclear.
  • Contrast-enhanced magnetic resonance imaging revealed a strongly enhancing single-lobed large cyst located in the deep white matter, under the solid part of the tumor attached to the dura mater of the left frontal lobe.
  • Both the solid and cystic portions of the tumor were surgically removed.
  • Histologically, the cyst wall was composed of gliosis representing a rough accumulation of reactive astrocytes, lymphocytes, and small capillary vessels in edematous parenchyma, but no tumor cells.
  • The present case and previous reports suggest that the cyst does not contain tumor cells, even if strongly depicted on contrast-enhanced neuroimaging, and that a thickly enhancing cyst wall indicates gliosis with accumulation of numerous small vessels.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Diseases / diagnosis. Brain Neoplasms / diagnosis. Cysts / diagnosis
  • [MeSH-minor] Arachnoid / pathology. Astrocytes / pathology. Capillaries / pathology. Cerebral Cortex / pathology. Contrast Media. Dura Mater / pathology. Frontal Lobe / pathology. Gliosis / pathology. Humans. Image Enhancement. Infant. Lymphocytes / pathology. Magnetic Resonance Imaging. Male. Pia Mater / pathology

  • Genetic Alliance. consumer health - Desmoplastic Infantile Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18352787.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


80. Buccoliero AM, Franchi A, Castiglione F, Gheri CF, Mussa F, Giordano F, Genitori L, Taddei GL: Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology; 2009 Feb;29(1):25-30
Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study.
  • Subependymal giant-cell astrocytoma (SEGA) is a rare intra-ventricular low-grade tumor which frequently occurs as a manifestation of tuberous sclerosis complex.
  • The histogenesis of SEGA is controversial and its astrocytic nature has been doubted.
  • First studies suggested the astrocytic nature of SEGA while several recent reports demonstrate its glio-neuronal nature.
  • We suggest moving it into the group of mixed glio-neuronal tumors under the denomination of subependymal giant cell tumor.
  • [MeSH-major] Astrocytoma / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adolescent. Brain Neoplasms / chemistry. Brain Neoplasms / classification. Brain Neoplasms / pathology. Brain Neoplasms / ultrastructure. Cerebral Ventricle Neoplasms / chemistry. Cerebral Ventricle Neoplasms / classification. Cerebral Ventricle Neoplasms / pathology. Cerebral Ventricle Neoplasms / ultrastructure. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Intermediate Filaments / ultrastructure. Male. Nerve Tissue Proteins / analysis. Neurofilament Proteins / analysis. Neuroglia / pathology. Neuroglia / ultrastructure. Phosphopyruvate Hydratase / analysis. Synaptophysin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564101.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Neurofilament Proteins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


81. Kinjo S, Yokoo H, Hirato J, Nakazato Y: Anaplastic astrocytoma with eosinophilic granular cells. Neuropathology; 2007 Oct;27(5):457-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytoma with eosinophilic granular cells.
  • On magnetic resonance imaging, a contrast-enhanced tumor in the left frontal lobe with perifocal edema was noted.
  • Thus, the tumor was histologically diagnosed as anaplastic astrocytoma.
  • The MIB-1 labeling index of the highest area of the tumor was 22%, while that of granular cells was 2.1%.
  • Such structures are relatively common in oligodendroglial tumors; however, they are extremely rare in astrocytic tumors.
  • The present case should also be discriminated from granular cell astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018480.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


82. Moser JJ, Fritzler MJ, Rattner JB: Primary ciliogenesis defects are associated with human astrocytoma/glioblastoma cells. BMC Cancer; 2009 Dec 17;9:448
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ciliogenesis defects are associated with human astrocytoma/glioblastoma cells.
  • The expression and function of primary cilia in cancer cells has now become a focus of attention but has not been studied in astrocytomas/glioblastomas.
  • To begin to address this issue, we compared the structure and expression of primary cilia in a normal human astrocyte cell line with five human astrocytoma/glioblastoma cell lines.
  • METHODS: Cultured normal human astrocytes and five human astrocytoma/glioblastoma cell lines were examined for primary cilia expression and structure using indirect immunofluorescence and electron microscopy.
  • Importantly, we document that in each of the five astrocytoma/glioblastoma cell lines fully formed primary cilia are either expressed at a very low level, are completely absent or have aberrant forms, due to incomplete ciliogenesis.
  • Our finding that the formation of the primary cilium is disrupted in cells derived from astrocytoma/glioblastoma tumors provides the first evidence that altered primary cilium expression and function may be part of some malignant phenotypes.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1999 Dec;155(6):1941-51 [10595924.001]
  • [Cites] Nat Med. 2009 Sep;15(9):1055-61 [19701205.001]
  • [Cites] Med Electron Microsc. 2000;33(3):109-14 [11810467.001]
  • [Cites] J Cell Sci. 2002 May 1;115(Pt 9):1825-35 [11956314.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • [Cites] Trends Cell Biol. 2002 Dec;12(12):551-5 [12495842.001]
  • [Cites] Arch Histol Cytol. 2003 May;66(2):145-53 [12846554.001]
  • [Cites] Cell Biol Int. 2004;28(2):125-30 [14984758.001]
  • [Cites] Int Rev Cytol. 2004;234:101-41 [15066374.001]
  • [Cites] J Cell Biol. 2004 Aug 30;166(5):637-43 [15337773.001]
  • [Cites] Cell Motil. 1985;5(3):175-93 [4005941.001]
  • [Cites] J Cell Biol. 1987 Feb;104(2):289-302 [2879846.001]
  • [Cites] J Cell Sci. 1987 Sep;88 ( Pt 2):185-203 [2826509.001]
  • [Cites] Anat Rec. 1991 Oct;231(2):145-55 [1746715.001]
  • [Cites] J Submicrosc Cytol Pathol. 1994 Jan;26(1):91-102 [8149337.001]
  • [Cites] Cell Biol Int. 1996 Jan;20(1):73-81 [8936410.001]
  • [Cites] EMBO J. 1998 Jul 1;17(13):3505-11 [9649421.001]
  • [Cites] Curr Biol. 1999 Apr 22;9(8):445-8 [10226030.001]
  • [Cites] Development. 1999 Jun;126(14):3089-100 [10375501.001]
  • [Cites] Arch Histol Cytol. 1999 Aug;62(3):219-29 [10495876.001]
  • [Cites] J Cell Biol. 1962 Nov;15:363-77 [13978319.001]
  • [Cites] Diabetes. 2005 May;54(5):1581-7 [15855349.001]
  • [Cites] Nat Cell Biol. 2005 May;7(5):517-24 [15852003.001]
  • [Cites] Nature. 2005 Oct 13;437(7061):1018-21 [16136078.001]
  • [Cites] PLoS Genet. 2005 Oct;1(4):e53 [16254602.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6463-7 [16818613.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Sep;291(3):G500-9 [16899714.001]
  • [Cites] Dev Genes Evol. 2006 Sep;216(9):537-42 [16534625.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2006;7:125-48 [16722803.001]
  • [Cites] Annu Rev Physiol. 2007;69:377-400 [17009929.001]
  • [Cites] PLoS Genet. 2007 Jan 5;3(1):e8 [17206865.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1255-7 [17604715.001]
  • [Cites] Curr Biol. 2007 Jul 3;17(13):1134-9 [17600711.001]
  • [Cites] Science. 2007 Jul 20;317(5836):372-6 [17641202.001]
  • [Cites] J Cell Biol. 2007 Jul 30;178(3):363-9 [17646400.001]
  • [Cites] Curr Biol. 2007 Sep 18;17(18):1586-94 [17825558.001]
  • [Cites] J Comp Neurol. 2007 Dec 10;505(5):562-71 [17924533.001]
  • [Cites] J Cell Biol. 2007 Oct 22;179(2):321-30 [17954613.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):1-4 [17960586.001]
  • [Cites] Front Biosci. 2008;13:2633-52 [17981739.001]
  • [Cites] Curr Biol. 2007 Nov 20;17(22):R963-5 [18029250.001]
  • [Cites] Eur J Cell Biol. 2008 Mar;87(3):137-46 [18171590.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2058-61 [18381407.001]
  • [Cites] Science. 2008 Jun 27;320(5884):1777-81 [18497258.001]
  • [Cites] Dev Cell. 2008 Aug;15(2):187-97 [18694559.001]
  • [Cites] Hum Mol Genet. 2008 Dec 1;17(23):3796-805 [18772192.001]
  • [Cites] Glia. 2009 Jan 15;57(2):136-52 [18709646.001]
  • [Cites] Am J Hum Genet. 2008 Nov;83(5):559-71 [18950740.001]
  • [Cites] Microsc Res Tech. 2009 Jan;72(1):42-8 [18837435.001]
  • [Cites] Dev Biol. 2009 Jan 1;325(1):24-32 [18930042.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):422-30 [19147554.001]
  • [Cites] Mol Biol Cell. 2009 Feb;20(4):1150-66 [19109428.001]
  • [Cites] J Cell Sci. 2009 Apr 15;122(Pt 8):1081-90 [19299460.001]
  • [Cites] Curr Biol. 2009 Jun 23;19(12):1005-11 [19481458.001]
  • [Cites] Nat Med. 2009 Sep;15(9):1062-5 [19701203.001]
  • [Cites] Mol Biochem Parasitol. 2001 Jun;115(1):1-17 [11377735.001]
  • (PMID = 20017937.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806408
  •  go-up   go-down


83. Axelsen JB, Lotem J, Sachs L, Domany E: Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc Natl Acad Sci U S A; 2007 Aug 7;104(32):13122-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cancers analyzed include brain (astrocytoma and glioblastoma), breast, colon, endometrium, kidney, liver, lung, ovary, prostate, skin, and thyroid cancers.
  • Different types of cancers, including different brain cancers arising from the same lineage, showed differences in the tissue-selective genes they overexpressed.
  • Melanomas overexpressed the highest number of brain-selective genes and this may contribute to melanoma metastasis to the brain.
  • Of all of the genes with tissue-selective expression, those selectively expressed in testis showed the highest frequency of genes that are overexpressed in at least two types of cancer.
  • Cancers aberrantly expressing such genes may acquire phenotypic alterations that contribute to cancer cell viability, growth, and metastasis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2238-42 [12399967.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5):513-7 [12407516.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:496-501 [12454644.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):825-33 [12724292.001]
  • [Cites] Cancer Immun. 2004 Jan 23;4:1 [14738373.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1799-806 [12969976.001]
  • [Cites] Curr Opin Oncol. 2004 May;16(3):211-4 [15069314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7 [15075390.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16022-7 [15505217.001]
  • [Cites] PLoS Biol. 2004 Dec;2(12):e427 [15562319.001]
  • [Cites] Bioinformatics. 2005 Mar 1;21(5):650-9 [15388519.001]
  • [Cites] DNA Res. 2004 Oct 31;11(5):335-44 [15747581.001]
  • [Cites] World J Gastroenterol. 2005 Apr 28;11(16):2390-7 [15832406.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):703-13 [15963951.001]
  • [Cites] Genomics. 2005 Aug;86(2):127-41 [15950434.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7234-42 [16243793.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18556-61 [16339305.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19069-74 [16354839.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):820-7 [16424014.001]
  • [Cites] J Mol Diagn. 2006 Feb;8(1):51-61 [16436634.001]
  • [Cites] Cancer Cell. 2006 Feb;9(2):121-32 [16473279.001]
  • [Cites] Endocrinology. 2006 Mar;147(3):1097-121 [16306079.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2129-37 [16489013.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Neurogenetics. 2006 May;7(2):67-80 [16572319.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5278-86 [16707453.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Jul;35(1):65-71 [16498083.001]
  • [Cites] BMC Genomics. 2006;7:92 [16638148.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Oncogene. 2006 Dec 14;25(59):7663-72 [16847453.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]
  • [ErratumIn] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15168. Bock-Axelsen, Jacob [corrected to Bock, Jacob Bock]
  • (PMID = 17664417.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1941809
  •  go-up   go-down


84. Xu P, Pu PY, Kang CS, Jia ZF, Zhou X, Wang GX: [Differential expression of Notch1 and Notch2 in astrocytoma and medulloblastoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Jul;37(7):450-3
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential expression of Notch1 and Notch2 in astrocytoma and medulloblastoma].
  • OBJECTIVE: To detect the differential expression of Notch1 and Notch2 in human astrocytoma and medulloblastoma; and to study the role of Notch1 and Notch2 in the development of both tumors.
  • METHODS: Immunohistochemical staining (SP method) and Western blot analysis were used to detect Notch1 and Notch2 expression in tissue arrays and freshly resected samples of normal brain tissue, astrocytoma and medulloblastoma.
  • RESULTS: Notch1 and Notch2 were negative in normal human brain tissue.
  • The percentage of positive tumor cells and expression level of Notch1 increased with higher histologic grade (r = 0.859, P < 0.05).
  • CONCLUSIONS: Notch1 and Notch2 show differential expression in astrocytoma and medulloblastoma.
  • This may be related to their different functional activities during the process of brain development.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Medulloblastoma / metabolism. Receptor, Notch1 / metabolism. Receptor, Notch2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / metabolism. Brain Neoplasms / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035115.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Notch1; 0 / Receptor, Notch2
  •  go-up   go-down


85. Brehar FM, Ciurea AV, Zarnescu O, Bleotu C, Gorgan RM, Dragu D, Matei L: Infiltrating growing pattern xenografts induced by glioblastoma and anaplastic astrocytoma derived tumor stem cells. Chirurgia (Bucur); 2010 Sep-Oct;105(5):685-94
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating growing pattern xenografts induced by glioblastoma and anaplastic astrocytoma derived tumor stem cells.
  • OBJECTIVE: The number of evidences regarding the role of tumor stem cells (TSC) in the initiation and progression of high-grade astrocytomas became more and more numerous in the last years.
  • This issue has been intensively tested in glioblastoma, but little attention has been paid for anaplastic astrocytoma.
  • The main objective of this paper was to study the morphological characteristics of the xenografts developed from glioblastoma and anaplastic astrocytoma derived cancer stem cells.
  • METHODS: The authors of this study successfully isolated and partial characterized primary cultures of glioblastoma and anaplastic astrocytoma derived TSC.
  • RESULTS: The tumor xenografts which have been established in nude mice using TSC had different characteristics when compared with U87 xenografts previously developed by our group, and depend of the origin type of the tumors (glioblastoma versus anaplastic astrocytoma).
  • The diffuse growing pattern and cells infiltration have been more pronounced in both anaplastic astrocytoma and glioblastoma derived TSC xenografts compared with U87 line xenografts.
  • CONCLUSION: Our results support the hypothesis regarding the role of TSC in the infiltration process of glioblastoma and anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplastic Stem Cells / pathology. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21141095.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  •  go-up   go-down


86. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer; 2006 Jan 1;106(1):172-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
  • BACKGROUND: A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS).
  • Time to tumor progression ranged from 2-19 months (median, 4 mos; 95% CI, 2-6 mos).
  • CONCLUSIONS: CYC demonstrated modest efficacy with acceptable toxicity in this cohort of adult patients with recurrent anaplastic astrocytoma, all of whom had failed prior TMZ chemotherapy.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Anaplasia. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Prospective Studies

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323194.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


87. Bence M, Kereszturi E, Mozes V, Sasvari-Szekely M, Keszler G: Hypoxia-induced transcription of dopamine D3 and D4 receptors in human neuroblastoma and astrocytoma cells. BMC Neurosci; 2009;10:92
Genetic Alliance. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia-induced transcription of dopamine D3 and D4 receptors in human neuroblastoma and astrocytoma cells.
  • BACKGROUND: Dopaminergic pathways that influence mood and behaviour are severely affected in cerebral hypoxia.
  • In order to clarify the hypoxic sensitivity of key dopaminergic genes, we aimed to study their transcriptional regulation in the context of neuroblastoma and astrocytoma cell lines exposed to 1% hypoxia.
  • [MeSH-minor] Astrocytoma. Blotting, Western. Cell Line, Tumor. Gene Transfer Techniques. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / genetics. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Immunohistochemistry. Neuroblastoma. Reverse Transcriptase Polymerase Chain Reaction. Transcriptional Activation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hypertens. 2003 Jan;21(1):199-207 [12544452.001]
  • [Cites] Sleep Breath. 2002 Dec;6(4):205-10 [12524574.001]
  • [Cites] Neuron. 2003 Jul 3;39(1):43-56 [12848931.001]
  • [Cites] Biol Neonate. 2003;84(3):222-31 [14504446.001]
  • [Cites] Drug News Perspect. 2003 Oct;16(8):497-503 [14668947.001]
  • [Cites] Biochem Pharmacol. 2004 Mar 1;67(5):947-55 [15104248.001]
  • [Cites] Synapse. 2004 Nov;54(2):92-101 [15352134.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):41966-74 [15280364.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3772-6 [2023928.001]
  • [Cites] Stroke. 1995 Jun;26(6):1093-100 [7762028.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12969-73 [8917528.001]
  • [Cites] Kidney Int. 1997 Feb;51(2):527-35 [9027733.001]
  • [Cites] Biochem J. 1997 Oct 15;327 ( Pt 2):419-23 [9359410.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jun 16;259(3):523-6 [10364451.001]
  • [Cites] Brain Res Mol Brain Res. 2004 Nov 4;130(1-2):115-23 [15519682.001]
  • [Cites] Biol Psychiatry. 2004 Nov 1;56(9):691-7 [15522254.001]
  • [Cites] J Exp Med. 2005 Jan 3;201(1):105-15 [15630139.001]
  • [Cites] Glia. 2005 Dec;52(4):336-43 [16078234.001]
  • [Cites] Hum Mutat. 2006 Jan;27(1):1-13 [16320307.001]
  • [Cites] Mol Cell. 2006 Feb 17;21(4):521-31 [16483933.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 19;343(4):1002-8 [16579968.001]
  • [Cites] BMC Mol Biol. 2006;7:18 [16723017.001]
  • [Cites] J Neurosci. 2007 Jan 10;27(2):412-21 [17215402.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2007 Mar 5;144B(2):231-6 [17171658.001]
  • [Cites] Cancer Cell. 2007 Apr;11(4):335-47 [17418410.001]
  • [Cites] Endocrinology. 2007 May;148(5):2563-70 [17317773.001]
  • [Cites] Neurotox Res. 2007 Jan;11(1):61-72 [17449449.001]
  • [Cites] J Neurosci. 2007 Jun 6;27(23):6320-32 [17554006.001]
  • [Cites] J Neurol Sci. 2007 Jun 15;257(1-2):160-5 [17316693.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]
  • [Cites] Eur J Neurosci. 2007 Sep;26(6):1489-99 [17880389.001]
  • [Cites] Free Radic Biol Med. 2008 Feb 15;44(4):657-70 [18061585.001]
  • [Cites] Mol Cell Endocrinol. 2008 Jul 16;289(1-2):23-8 [18472212.001]
  • [Cites] Prog Brain Res. 2008;172:73-98 [18772028.001]
  • [Cites] Pflugers Arch. 1999 Nov;438(6):750-9 [10591061.001]
  • [Cites] Eur J Neurosci. 1999 Dec;11(12):4159-70 [10594641.001]
  • [Cites] Brain Res Mol Brain Res. 2000 Feb 22;75(2):264-70 [10686347.001]
  • [Cites] J Biol Chem. 2000 Mar 10;275(10):6922-7 [10702253.001]
  • [Cites] J Neurosci. 2000 Oct 1;20(19):7377-83 [11007896.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1297-310 [11158315.001]
  • [Cites] Exp Cell Res. 2001 Apr 15;265(1):114-24 [11281649.001]
  • [Cites] Acta Neuropathol. 2001 Mar;101(3):271-6 [11307627.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7558-63 [11390978.001]
  • [Cites] Biol Neonate. 2001 Jul;80(1):68-73 [11474153.001]
  • [Cites] Respir Physiol. 2001 Nov 15;128(3):263-76 [11718758.001]
  • [Cites] Science. 2002 Feb 1;295(5556):858-61 [11823643.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 19;1574(2):152-6 [11955624.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(21):7405-16 [12370288.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15729-34 [12438650.001]
  • [Cites] Neuroscience. 2003;117(2):417-25 [12614682.001]
  • (PMID = 19653907.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DRD3 protein, human; 0 / DRD4 protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Receptors, Dopamine D3; 137750-34-6 / Receptors, Dopamine D4
  • [Other-IDs] NLM/ PMC3224682
  •  go-up   go-down


88. Balkanov AS, Makarenko MF, Poliakov PIu, Kachkov IA: [Results of hyperfractionated radiation therapy used in combination with lomustin in malignant gliomas of the brain]. Zh Vopr Neirokhir Im N N Burdenko; 2005 Jul-Sep;(3):14-16; discussion 16-7
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of hyperfractionated radiation therapy used in combination with lomustin in malignant gliomas of the brain].
  • The postoperative use of lomustin, a nitrosourea agent, was investigated for its impact on the efficiency of hyperfractionated radiation therapy performed in patients with glioblastoma and anaplastic astrocytoma of the brain.
  • A total of 35 patients (26 and 9 patients with glioblastoma and anaplastic astrocytoma, respectively) were followed up.
  • Lomustin in combination with hyperfractionated radiation therapy was found to have no effect on the survival of patients with glioblastoma and anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioma / drug therapy. Glioma / radiotherapy. Lomustine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485820.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


89. Khalatbari M, Borghei-Razavi H, Shayanfar N, Behzadi AH, Sepehrnia A: Collision tumor of meningioma and malignant astrocytoma. Pediatr Neurosurg; 2010;46(5):357-61
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of meningioma and malignant astrocytoma.
  • The pathology of tumors reported collision tumors composed of meningioma and malignant astrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389747.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


90. Santel T, Pflug G, Hemdan NY, Schäfer A, Hollenbach M, Buchold M, Hintersdorf A, Lindner I, Otto A, Bigl M, Oerlecke I, Hutschenreuther A, Sack U, Huse K, Groth M, Birkemeyer C, Schellenberger W, Gebhardt R, Platzer M, Weiss T, Vijayalakshmi MA, Krüger M, Birkenmeier G: Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity. PLoS One; 2008;3(10):e3508
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity.
  • METHODOLOGY/PRINCIPAL FINDINGS: Cultures of whole blood cells and tumor cell lines (PC-3, JIM-1, MDA-MD 231 and 1321N1) were set up to investigate the effect of selected polyphenols, including curcumin, on the LPS-induced cytokine production (cytometric bead-based array), cell proliferation (WST-1 assay), cytosolic Glo1 and Glo2 enzymatic activity, apoptosis/necrosis (annexin V-FITC/propidium iodide staining; flow cytometric analysis) as well as GSH and ATP content.
  • Moreover, whereas curcumin was found to hamper the growth of breast cancer (JIMT-1, MDA-MB-231), prostate cancer PC-3 and brain astrocytoma 1321N1 cells, no effect on growth or vitality of human primary hepatocytes was elucidated.
  • Curcumin decreased D-lactate release by tumor cells, another clue for inhibition of intracellular Glo1.
  • This may account for curcumin's potency as an anti-inflammatory and anti-tumor agent.

  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol Interact. 2000 Aug 15;128(1):19-38 [10996298.001]
  • [Cites] J Cell Biochem. 2007 May 15;101(2):307-20 [17171638.001]
  • [Cites] FEBS Lett. 2001 Apr 20;495(1-2):131-6 [11322961.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2513-8 [11489834.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45770-5 [12226095.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1053-62 [12393461.001]
  • [Cites] J Hepatol. 2003 Apr;38(4):476-82 [12663240.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):363-98 [12680238.001]
  • [Cites] Crit Rev Food Sci Nutr. 2004;44(2):97-111 [15116757.001]
  • [Cites] Biochem Pharmacol. 2004 Oct 1;68(7):1433-42 [15345333.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Anal Biochem. 1980 Feb;102(1):39-46 [7356162.001]
  • [Cites] Methods Enzymol. 1982;90 Pt E:535-41 [7154966.001]
  • [Cites] Biochim Biophys Acta. 1985 May 20;829(1):109-18 [3888271.001]
  • [Cites] Biochim Biophys Acta. 1985 May 20;829(1):119-26 [3888272.001]
  • [Cites] Mech Ageing Dev. 1989 Apr;48(1):63-71 [2725076.001]
  • [Cites] Neurobiol Aging. 2007 Jul;28(7):1044-50 [16781798.001]
  • [Cites] Int J Oncol. 2007 Jul;31(1):161-8 [17549417.001]
  • [Cites] Adv Exp Med Biol. 2007;595:105-25 [17569207.001]
  • [Cites] Adv Exp Med Biol. 2007;595:227-43 [17569214.001]
  • [Cites] Adv Exp Med Biol. 2007;595:321-41 [17569218.001]
  • [Cites] Biochem Pharmacol. 2007 Aug 15;74(4):579-89 [17617381.001]
  • [Cites] Free Radic Biol Med. 2007 Aug 15;43(4):568-80 [17640567.001]
  • [Cites] J Neurochem. 2007 Aug;102(4):1095-104 [17472706.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):724-8 [18089954.001]
  • [Cites] Biochem J. 2008 Feb 15;410(1):147-55 [17953519.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2008 Feb;56(2):162-7 [18239300.001]
  • [Cites] Biochem Pharmacol. 2008 Feb 15;75(4):787-809 [17900536.001]
  • [Cites] Aging Cell. 2008 Mar;7(2):260-9 [18221415.001]
  • [Cites] Bioorg Med Chem. 2008 Apr 1;16(7):3969-75 [18258440.001]
  • [Cites] World J Gastroenterol. 2008 Apr 14;14(14):2174-8 [18407590.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jul;62(2):215-26 [17896107.001]
  • [Cites] Mol Nutr Food Res. 2008 Jun;52 Suppl 1:S103-27 [18496811.001]
  • [Cites] Biochem Pharmacol. 2008 Sep 1;76(5):631-44 [18625205.001]
  • [Cites] Biomed Pharmacother. 2008 Nov;62(9):630-6 [18325727.001]
  • [Cites] J Neurochem. 2008 Jun 1;105(6):2489-500 [18399961.001]
  • [Cites] J Agric Food Chem. 2001 Mar;49(3):1464-74 [11312881.001]
  • [Cites] J Clin Neuroophthalmol. 1991 Mar;11(1):58-61 [1827463.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):233-40 [1904465.001]
  • [Cites] Biochem Pharmacol. 1996 May 17;51(10):1365-72 [8787553.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5533-8 [9576917.001]
  • [Cites] Chem Biol Interact. 1998 Apr 24;111-112:263-75 [9679560.001]
  • [Cites] Indian J Gastroenterol. 1999 Jul-Sep;18(3):118-21 [10407566.001]
  • [Cites] Arch Biochem Biophys. 1959 May;82(1):70-7 [13650640.001]
  • [Cites] Cell Biochem Funct. 2004 Nov-Dec;22(6):343-52 [15386533.001]
  • [Cites] Science. 1956 Aug 10;124(3215):269-70 [13351639.001]
  • [Cites] J Agric Food Chem. 2005 Feb 23;53(4):959-63 [15713005.001]
  • [Cites] Ann N Y Acad Sci. 2005 May;1042:372-8 [15965083.001]
  • [Cites] Ann N Y Acad Sci. 2005 Jun;1043:135-45 [16037232.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1842-53 [16087329.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36708-13 [16141205.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38720-8 [16172117.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:206-17 [16387689.001]
  • [Cites] J Nat Prod. 2006 Mar;69(3):351-5 [16562833.001]
  • [Cites] Biochem Pharmacol. 2006 May 14;71(10):1397-421 [16563357.001]
  • [Cites] J Biol Chem. 2006 Apr 28;281(17):11864-71 [16505483.001]
  • [Cites] Antimicrob Agents Chemother. 2006 May;50(5):1859-60 [16641461.001]
  • [Cites] Free Radic Biol Med. 2006 Jul 1;41(1):65-76 [16781454.001]
  • [Cites] Crit Care Med. 2006 Jul;34(7):1874-82 [16715036.001]
  • [Cites] Mol Cell Biochem. 2006 Oct;290(1-2):87-96 [16770527.001]
  • [Cites] J Am Chem Soc. 2007 Jan 31;129(4):873-80 [17243824.001]
  • [Cites] J Clin Immunol. 2007 Jan;27(1):19-35 [17211725.001]
  • [ErratumIn] PLoS One. 2011;6(7). doi:10.1371/annotation/0eb2b9f3-1006-4dcd-ad61-367310a2686a. Hutschenreuter, Antje [corrected to Hutschenreuther, Antje]
  • (PMID = 18946510.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Interleukin-1beta; 0 / Lipopolysaccharides; 0 / Phenols; 0 / Polyphenols; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 4.4.1.5 / Lactoylglutathione Lyase; IT942ZTH98 / Curcumin
  • [Other-IDs] NLM/ PMC2567432
  •  go-up   go-down


91. Zakrzewski K, Biernat W, Liberski PP, Polis L, Nowoslawska E: Pilocytic astrocytoma as a predominant component of a recurrent complex type DNT. Folia Neuropathol; 2009;47(3):284-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilocytic astrocytoma as a predominant component of a recurrent complex type DNT.
  • Dysembryoplastic neuroepithelial tumour (DNT) is a benign lesion of the cerebral hemispheres usually presenting minimal biological activity after surgical excision.
  • We report an unusual case of a 7-year-old girl with a temporal lobe DNT, which recurred four years after subtotal resection of the tumour.
  • In the recurrent lesion we identified pilocytic astrocytoma (PA) as a predominant component of the tumour.
  • Clinical presentation of the primary tumour consisted of partial simple seizures, while the recurrent tumour manifested with headache and vomiting.
  • We conclude that patients with incompletely removed DNT may suffer local recurrence of that tumour.
  • In rare cases development of a secondary, histologically different neoplasm may also occur.

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19813149.001).
  • [ISSN] 1641-4640
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


92. Arulrajah S, Huisman TA: Pilomyxoid astrocytoma of the spinal cord with cerebrospinal fluid and peritoneal metastasis. Neuropediatrics; 2008 Aug;39(4):243-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilomyxoid astrocytoma of the spinal cord with cerebrospinal fluid and peritoneal metastasis.
  • Pilomyxoid astrocytoma (PMA) is a recently described rare tumor which is a variant of pilocytic astrocytoma (PA).
  • We report on a female child with cervical cord PMA with diffuse leptomeningeal metastasis involving the brain and spinal cord.
  • Two years later she presented with peritoneal carcinomatoses which was consistent with metastatic tumor via a ventriculoperitoneal (VP) shunt.
  • [MeSH-major] Astrocytoma / cerebrospinal fluid. Astrocytoma / pathology. Carcinoma / secondary. Peritoneal Neoplasms / secondary. Spinal Cord Neoplasms / cerebrospinal fluid. Spinal Cord Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165714.001).
  • [ISSN] 0174-304X
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


93. Tibbetts KM, Emnett RJ, Gao F, Perry A, Gutmann DH, Leonard JR: Histopathologic predictors of pilocytic astrocytoma event-free survival. Acta Neuropathol; 2009 Jun;117(6):657-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic predictors of pilocytic astrocytoma event-free survival.
  • Pilocytic astrocytoma (PA) is the most common pediatric brain tumor.
  • Lastly, we did find a statistical trend between EFS and the number of CD68+ cells, suggesting that non-neoplastic elements of the tumor microenvironment may influence subsequent growth and clinical recurrence.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Brain / pathology. Brain / physiopathology. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Immunohistochemistry. Infant. Male. Mitotic Index. Retrospective Studies. Signal Transduction. Tumor Suppressor Protein p53 / metabolism. Young Adult


94. Neves AM, Thompson G, Carvalheira J, Trindade JC, Rueff J, Caetano JM, Casey JW, Hermouet S: Detection and quantitative analysis of human herpesvirus in pilocytic astrocytoma. Brain Res; 2008 Jul 24;1221:108-14
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and quantitative analysis of human herpesvirus in pilocytic astrocytoma.
  • We investigated the hypothetical role of human herpesviruses (HHVs) in tumour formation of the cerebellum.
  • Thirty-five samples of pilocytic astrocytoma and 10 control samples of cerebellum from patients who died of unrelated diseases were examined.
  • In summary, EBV was the most frequent HHV detected in pilocytic astrocytoma, but at very low levels.
  • According to the actually accepted threshold the results suggest that EBV cannot be considered responsible for tumorigenesis of pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / virology. Cerebellar Neoplasms / virology. DNA, Viral / genetics. Herpesviridae / genetics. Herpesviridae Infections / complications. Herpesviridae Infections / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565499.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral; EC 2.7.7.- / DNA Polymerase III; EC 2.7.7.- / DNA polymerase A
  •  go-up   go-down


95. Chen J, Xia J, Zhou YC, Xia LM, Zhu WZ, Zou ML, Feng DY, Wang CY: [Correlation between magnetic resonance diffusion weighted imaging and cell density in astrocytoma]. Zhonghua Zhong Liu Za Zhi; 2005 May;27(5):309-11
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between magnetic resonance diffusion weighted imaging and cell density in astrocytoma].
  • OBJECTIVE: To evaluate the apparent diffusion coefficients (ADC) in magnetic resonance diffusion weighted imaging with echo-planar technique in depicting the tumor cellularity and grading of astrocytoma.
  • METHODS: Thirty-four astrocytoma patients including 18 male and 16 female with age from 10 to 73 years (mean 38.4 years) were examined by MRI and eventually proved by surgical resection and pathological examination.
  • Of them, 26 had low-grade (grade I, II) astrocytoma and 8 high-grade (grade III, IV) astrocytoma.
  • ADC value of astrocytoma was determined on magnetic resonance diffusion weighted images.
  • Cellularity of the astrocytoma was analyzed using Adobe Photoshop 7.0.1 software.
  • ADC value of the astrocytoma was significantly and negatively correlated with its cellularity (r = -0.535, P = 0.001).
  • CONCLUSION: ADC value of astrocytoma is significantly and negatively correlated with its cellularity.
  • Magnetic resonance diffusion weighted imaging may well be highly potential in predicting the degree of astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Count. Child. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Humans. Image Processing, Computer-Assisted. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996330.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


96. Miyamoto S, Mikuni N, Yamada K, Takahashi JA, Hashimoto N: Radical resection for intrinsic midbrain pilocytic astrocytoma: report of two cases. Acta Neurochir (Wien); 2005 Jan;147(1):93-7; discussion 97
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical resection for intrinsic midbrain pilocytic astrocytoma: report of two cases.
  • It is known that the prognosis of pilocytic astrocytoma is relatively good if radical resection can be achieved without severe complications.
  • In order to remove pilocytic astrocytoma within the midbrain radically, we used microsurgical techniques.
  • The subtemporal approach was used with a point of entry on the lateral surface of the midbrain just behind the cerebral peduncle.
  • Major vessels were preserved, followed by resection of the intrinsic tumor making the cleavage between tumour and midbrain.
  • FINDINGS: In both patients, intrinsic pilocytic astrocytoma was grossly totally removed with minimal permanent morbidity.
  • They have been able to maintain independent activities in their daily lives without tumor recurrance.
  • CONCLUSIONS: Surgical cure can be accomplished in some cases of midbrain pilocytic astrocytoma, even if the lesions are intrinsic to the midbrain.
  • To remove the tumor totally without further neurological deficits, it is necessary to select a safe access or entrance point to the tumor, and to demarcate the gliotic plane between tumour and midbrain.
  • A long-term follow up with a larger number of patients is needed to establish the significance of radical resection for intrinsic midbrain pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Brain Stem Neoplasms / surgery. Microsurgery / methods
  • [MeSH-minor] Child. Humans. Male. Neoplasm Invasiveness. Thalamus / pathology. Thalamus / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15309583.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


97. Ooba H, Abe T, Kamida T, Anan M, Momii Y, Tokuuye K, Fujiki M: Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma. J Clin Neurosci; 2009 Dec;16(12):1641-3
Genetic Alliance. consumer health - Anaplastic Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.
  • This report presents a 70-year-old male who presented with a rare malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic astrocytoma.
  • To our knowledge, malignant fibrous histiocytosis caused by proton therapy has not been reported, therefore the clinical features of this complication are described and previous cases are reviewed.
  • [MeSH-minor] Aged. Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Humans. Magnetic Resonance Imaging / methods. Male

  • Genetic Alliance. consumer health - Histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766005.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


98. Moser JJ, Eystathioy T, Chan EK, Fritzler MJ: Markers of mRNA stabilization and degradation, and RNAi within astrocytoma GW bodies. J Neurosci Res; 2007 Dec;85(16):3619-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of mRNA stabilization and degradation, and RNAi within astrocytoma GW bodies.
  • The novelty of this study is the identification of GWBs in astrocytes and astrocytoma cells within cell bodies and cytoplasmic projections.
  • Astrocytoma GWBs exhibit complex heterogeneity with combinations of LSm4 and XRN1 as well as Ago2 and Dicer, key proteins involved in mRNA degradation and RNA interference, respectively.
  • Immunoprecipitation of astrocytoma GWBs suggested that Dicer, hDcp, LSm4, XRN1, SYNCRIP, and FMRP form a multiprotein complex.
  • GWBs are likely involved in a number of regulatory mRNA pathways in astrocytes and astrocytoma cells.
  • [MeSH-minor] Animals. Astrocytoma / genetics. Astrocytoma / metabolism. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Cell Line, Tumor. Cells, Cultured. DEAD-box RNA Helicases / genetics. DEAD-box RNA Helicases / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Endoribonucleases / genetics. Endoribonucleases / metabolism. Exoribonucleases / genetics. Exoribonucleases / metabolism. Fragile X Mental Retardation Protein / genetics. Fragile X Mental Retardation Protein / metabolism. Gene Expression Regulation / genetics. Heterogeneous-Nuclear Ribonucleoproteins / genetics. Heterogeneous-Nuclear Ribonucleoproteins / metabolism. Humans. Macromolecular Substances. Mice. Mice, Inbred C57BL. RNA-Binding Proteins / genetics. RNA-Binding Proteins / metabolism. Ribonuclease III. Ribonucleoproteins, Small Nuclear / genetics. Ribonucleoproteins, Small Nuclear / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17663465.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI 47859; United States / NIAMS NIH HHS / AR / AR 42455
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Fmr1 protein, mouse; 0 / Heterogeneous-Nuclear Ribonucleoproteins; 0 / Lsm4 protein, mouse; 0 / Macromolecular Substances; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Ribonucleoproteins, Small Nuclear; 0 / Syncrip protein, mouse; 139135-51-6 / Fragile X Mental Retardation Protein; EC 3.1.- / Endoribonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / Xrn1 protein, mouse; EC 3.1.26.3 / Dicer1 protein, mouse; EC 3.1.26.3 / Ribonuclease III; EC 3.6.4.13 / DEAD-box RNA Helicases
  •  go-up   go-down


99. Brandt C, Brechtelsbauer D, Bien CG, Reiners K: [Out-of-body experience as possible seizure symptom in a patient with a right parietal lesion]. Nervenarzt; 2005 Oct;76(10):1259, 1261-2
MedlinePlus Health Information. consumer health - Seizures.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Astrocytoma / diagnosis. Body Image. Brain Neoplasms / diagnosis. Depersonalization / diagnosis. Seizures / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epilepsia. 2004 Apr;45(4):391-4 [15030502.001]
  • [Cites] AMA Arch Neurol Psychiatry. 1958 Aug;80(2):199-220 [13558775.001]
  • [Cites] J Nerv Ment Dis. 1981 Jun;169(6):374-7 [7229635.001]
  • [Cites] Cephalalgia. 1999 Dec;19(10):886-96 [10668108.001]
  • [Cites] J Nerv Ment Dis. 1986 Oct;174(10):615-9 [3760852.001]
  • [Cites] Brain. 2004 Feb;127(Pt 2):243-58 [14662516.001]
  • [Cites] Arch Neurol. 1989 Oct;46(10):1080-8 [2679507.001]
  • [Cites] J Post Anesth Nurs. 1995 Feb;10(1):27-8 [7707249.001]
  • [Cites] Neurology. 1992 Jul;42(7 Suppl 6):44-51; discussion 52 [1630638.001]
  • [Cites] Anaesth Intensive Care. 2002 Jun;30(3):382-4 [12075653.001]
  • [Cites] Psychol Med. 1983 Aug;13(3):651-4 [6622616.001]
  • [Cites] Brain. 2004 Feb;127(Pt 2):239-42 [14726478.001]
  • (PMID = 15830175.001).
  • [ISSN] 0028-2804
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


100. Temel SG, Kahveci Z: Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. J Mol Histol; 2009 Oct;40(5-6):369-77
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma.
  • Cox-2 is cytokine-inducible in inflammatory cells and enhanced cox-2 expression has been attributed a key role in the development of edema and immunomodulation in pathologically altered brain tissues.
  • In normal cerebral cortex cox-2 is present only in neurons, but not in the glial or vascular endothelial cells.
  • For this purpose we employed dual immunohistochemistry for cox-2 and GFAP (astrocyte) or LCA-MAC (microglia-macrophage) in archival formalin-fixed, paraffin embedded human tissue diagnosed as oligodendroglioma and/or astrocytoma.
  • The results showed that cox-2 immunoreactivity is up-regulated in the neurons according to the tumor grade.
  • It may be speculated that the induction of cox-2 in microglia may contribute to the deleterious effects of prostanoids in cerebral edema formation during the progression of oligodendrogliomas.
  • [MeSH-major] Astrocytes / enzymology. Astrocytoma / enzymology. Cyclooxygenase 2 / metabolism. Microglia / enzymology. Oligodendroglioma / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20052522.001).
  • [ISSN] 1567-2387
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down






Advertisement